CN116287195A - Molecular marker for auxiliary diagnosis of cardiovascular and cerebrovascular diseases - Google Patents
Molecular marker for auxiliary diagnosis of cardiovascular and cerebrovascular diseases Download PDFInfo
- Publication number
- CN116287195A CN116287195A CN202310083186.0A CN202310083186A CN116287195A CN 116287195 A CN116287195 A CN 116287195A CN 202310083186 A CN202310083186 A CN 202310083186A CN 116287195 A CN116287195 A CN 116287195A
- Authority
- CN
- China
- Prior art keywords
- coronary heart
- heart disease
- onset
- patients
- cerebral apoplexy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 93
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 89
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 88
- 238000003745 diagnosis Methods 0.000 title claims abstract description 73
- 239000003147 molecular marker Substances 0.000 title abstract description 9
- 208000006011 Stroke Diseases 0.000 claims abstract description 344
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 334
- 230000002490 cerebral effect Effects 0.000 claims abstract description 269
- 206010008190 Cerebrovascular accident Diseases 0.000 claims abstract description 256
- 230000011987 methylation Effects 0.000 claims abstract description 250
- 238000007069 methylation reaction Methods 0.000 claims abstract description 250
- 208000013875 Heart injury Diseases 0.000 claims abstract description 73
- 238000004393 prognosis Methods 0.000 claims abstract description 67
- 238000012544 monitoring process Methods 0.000 claims abstract description 59
- 239000000090 biomarker Substances 0.000 claims abstract description 48
- 101150085595 FUT7 gene Proteins 0.000 claims abstract description 41
- 210000004369 blood Anatomy 0.000 claims abstract description 40
- 239000008280 blood Substances 0.000 claims abstract description 40
- 108091029430 CpG site Proteins 0.000 claims description 156
- 239000012634 fragment Substances 0.000 claims description 105
- 108020004414 DNA Proteins 0.000 claims description 104
- 230000000306 recurrent effect Effects 0.000 claims description 95
- 238000013178 mathematical model Methods 0.000 claims description 89
- 238000001514 detection method Methods 0.000 claims description 61
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 22
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 238000007477 logistic regression Methods 0.000 claims description 19
- 102000053602 DNA Human genes 0.000 claims description 16
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 16
- 238000007405 data analysis Methods 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000011156 evaluation Methods 0.000 abstract description 6
- 230000006607 hypermethylation Effects 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 67
- 210000000265 leukocyte Anatomy 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 28
- 208000031225 myocardial ischemia Diseases 0.000 description 27
- 230000000302 ischemic effect Effects 0.000 description 26
- 238000004820 blood count Methods 0.000 description 24
- 208000010125 myocardial infarction Diseases 0.000 description 23
- 206010002383 Angina Pectoris Diseases 0.000 description 22
- 201000010099 disease Diseases 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 18
- 230000003683 cardiac damage Effects 0.000 description 18
- 206010042434 Sudden death Diseases 0.000 description 17
- 230000002008 hemorrhagic effect Effects 0.000 description 13
- 230000007067 DNA methylation Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000012549 training Methods 0.000 description 12
- 239000013610 patient sample Substances 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 10
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 9
- 230000036541 health Effects 0.000 description 8
- 206010008092 Cerebral artery thrombosis Diseases 0.000 description 7
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 6
- 208000032382 Ischaemic stroke Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 6
- 101150018494 RPTOR gene Proteins 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 208000017667 Chronic Disease Diseases 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000012502 risk assessment Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 208000023516 stroke disease Diseases 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 208000001490 Dengue Diseases 0.000 description 2
- 206010012310 Dengue fever Diseases 0.000 description 2
- 206010061819 Disease recurrence Diseases 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 101000819497 Homo sapiens Alpha-(1,3)-fucosyltransferase 7 Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 208000025729 dengue disease Diseases 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012821 model calculation Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000191 radiation effect Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 208000014221 sudden cardiac arrest Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001196 time-of-flight mass spectrum Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a molecular marker for assisting in diagnosing cardiovascular and cerebrovascular diseases. The molecular marker for assisting in diagnosing cardiovascular and cerebrovascular diseases provided by the invention is a methylation biomarker, and the molecular marker is at least one of the following purposes: auxiliary diagnosis of cardiovascular and cerebrovascular diseases or early warning of cardiovascular and cerebrovascular diseases (such as coronary heart disease and cerebral apoplexy) before clinical onset, auxiliary evaluation of heart injury and cardiovascular and cerebrovascular prognosis monitoring. The invention discloses hypermethylation of FUT7 gene in blood of coronary heart disease patients, heart injury patients and coronary heart disease recurrence patients, hypomethylation of FUT7 gene in blood of cerebral apoplexy patients and cerebral apoplexy recurrence patients, and the blood is taken as a sample to early warn and distinguish cardiovascular and cerebrovascular patients with different clinical characteristics from healthy contrast, heart injury and cardiovascular and cerebrovascular disease recurrence and non-recurrence with different clinical characteristics before clinical onset.
Description
Technical Field
The invention relates to the field of medicine, in particular to a molecular marker for assisting in diagnosing cardiovascular and cerebrovascular diseases.
Background
Cardiovascular and cerebrovascular diseases are the general terms of cardiovascular and cerebrovascular diseases, and refer broadly to ischemic or hemorrhagic diseases of heart, brain and systemic tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, hypertension, etc. Cardiovascular and cerebrovascular diseases are common diseases seriously threatening the health of human beings, especially middle-aged and elderly people over 50 years old, and have the characteristics of high morbidity, high disability rate and high mortality rate. At present, the number of people dying from cardiovascular and cerebrovascular diseases worldwide is up to 1500 ten thousand people each year.
Coronary heart disease refers to heart disease caused by myocardial ischemia, hypoxia or necrosis due to stenosis, spasm or blockage of a lumen by coronary atherosclerosis, collectively referred to as coronary heart disease or coronary artery disease. Coronary heart disease is classified into 5 types according to clinical characteristics such as lesion sites, ranges, degrees and the like: (1) occult or asymptomatic myocardial ischemia: asymptomatic, but showing myocardial ischemia changes under resting, dynamic or loading electrocardiogram, or radionuclide myocardial imaging suggesting myocardial hypoperfusion, no tissue morphology changes; (2) angina pectoris: posttraumatic sternal pain caused by myocardial ischemia; (3) myocardial infarction: severe ischemic symptoms, acute ischemic necrosis of the myocardium due to coronary occlusion; (4) ischemic cardiomyopathy: chronic myocardial ischemia or necrosis causes myocardial fibrosis, manifested by increased heart, heart failure and cardiac arrhythmias; (5) sudden death: death due to sudden cardiac arrest is often caused by severe arrhythmias resulting from local electrophysiological disturbances in the ischemic myocardium. The main diagnosis method of the coronary heart disease at present comprises the following steps: (1) clinical characteristics: typically, the combination of the medical history and physical examination status of the inspector is used for preliminary diagnosis, but the specificity is very low; (2) imaging method: electrocardiography, echocardiography, and coronary angiography, but are often affected by physician experience and instrumentation; (3) The most commonly used coronary heart disease markers at present are as follows: myocardial injury markers, inflammatory factors, adhesion molecules and cytokine markers, plasma lipoprotein and apolipoprotein markers, coagulation related protein markers, and the like. Because a certain marker reflects only a certain disease mechanism of a disease, these markers are not widely accepted clinically.
Cerebral apoplexy is commonly called as apoplexy, and is an acute cerebrovascular disease, including ischemic cerebral apoplexy and hemorrhagic cerebral apoplexy. Ischemic cerebral apoplexy accounts for 60% -70% of all cerebral strokes, mainly due to cerebral vascular stenosis or occlusion caused by atherosclerosis, thereby causing cerebral ischemia and hypoxia, further causing ischemic necrosis or softening of localized cerebral tissue, patients are more than 40 years old, men are more female, and serious men can cause death. Hemorrhagic stroke is classified into cerebral hemorrhage and subarachnoid hemorrhage, and is mainly caused by long-term hypertension, aneurysm or congenital weakness of cerebral blood vessels, and the like, which cause cerebral blood vessel rupture and hemorrhage, and the blood presses normal brain tissues in the brain, so that the brain cannot perform normal functions, namely 'cerebral hemorrhage', and the death rate is higher. At present, imaging methods are often used for diagnosing cerebral apoplexy, such as CT and nuclear magnetic resonance examination, the sensitivity of CT to the cerebral arterial thrombosis is higher, but the sensitivity to the cerebral arterial thrombosis is only 16%, and the cerebral arterial thrombosis is not suitable for frequent use due to radiation; nuclear magnetic resonance examination has higher sensitivity to ischemic stroke than CT and no radiation effect, but has the disadvantage of lower feasibility, practicality and accessibility (equipment and trained personnel).
Coronary heart disease and cerebral apoplexy both belong to cardiovascular and cerebrovascular diseases. Most cardiovascular diseases can be prevented and treated, and are generally prevented by improving consciousness through popularization knowledge, avoiding exogenous stimulus factors and reasonably dietary moderate exercise, and the treatment effect is greatly dependent on early diagnosis and corresponding intervention measures. At present, the sensitivity and specificity of diagnostic markers for coronary heart disease and cerebral apoplexy are limited clinically, and particularly markers for early diagnosis are lacking, so that more sensitive and specific early molecular markers are urgently needed to be discovered. DNA methylation is a chemical modification important on genes that affects the regulatory process of gene transcription and nuclear structure.
Disclosure of Invention
The invention aims to provide application of FUT7 gene methylation level in auxiliary diagnosis of cardiovascular and cerebrovascular diseases.
In a first aspect, the invention claims a methylation biomarker.
The nucleotide sequence of the methylation biomarker claimed by the invention is all or part of fragments shown in the following (A1) - (A4) in the FUT7 gene:
(A1) A DNA fragment shown in SEQ ID No.1 or a DNA fragment having 80% or more identity thereto;
(A2) A DNA fragment shown in SEQ ID No.2 or a DNA fragment having 80% or more identity thereto;
(A3) A DNA fragment shown in SEQ ID No.3 or a DNA fragment having 80% or more identity thereto;
(A4) A DNA fragment shown in SEQ ID No.4 or a DNA fragment having 80% or more identity thereto;
the methylation marker comprises a CpG site located on the nucleotide sequence of the methylation marker as shown in any one of the following (B1) - (B7):
(B1) Any one or more CpG sites in 4 DNA fragments shown as SEQ ID No.1, SEQ ID No.2, SEQ ID No.3 and SEQ ID No.4 in the FUT7 gene;
the upper limit of "multiple CpG sites" as used herein is all CpG sites in the 4 DNA fragments shown in SEQ ID No.1 to SEQ ID No.4 in the FUT7 gene. All CpG sites in the DNA fragment shown in SEQ ID No.1 (see Table 1), all CpG sites in the DNA fragment shown in SEQ ID No.2 (see Table 2), all CpG sites in the DNA fragment shown in SEQ ID No.3 (see Table 3), and all CpG sites in the DNA fragment shown in SEQ ID No.4 (see Table 4).
(B2) All CpG sites on the DNA fragment shown in SEQ ID No.2 (see Table 2) and all CpG sites on the DNA fragment shown in SEQ ID No.4 (see Table 4) in the FUT7 gene;
(B3) All CpG sites on the DNA fragment shown in SEQ ID No.3 (see Table 3) and all CpG sites on the DNA fragment shown in SEQ ID No.4 (see Table 4) in the FUT7 gene;
(B4) All CpG sites on the DNA fragment shown in SEQ ID No.2 (see Table 2) and all CpG sites on the DNA fragment shown in SEQ ID No.3 (see Table 3) in the FUT7 gene;
(B5) All CpG sites on the DNA fragment shown in SEQ ID No.2 (see Table 2), all CpG sites on the DNA fragment shown in SEQ ID No.3 (see Table 3) and all CpG sites on the DNA fragment shown in SEQ ID No.4 (see Table 4) in the FUT7 gene;
(B6) All CpG sites (see Table 4) or any 17 or any 16 or any 15 or any 14 or any 13 or any 12 or any 11 or any 10 or any 9 or any 8 or any 7 or any 6 or any 5 or any 4 or any 3 or any 2 or any 1 CpG sites in the DNA fragment shown in SEQ ID No.4 in the FUT7 gene;
(B7) All or any 8 or any 7 or any 6 or any 5 or any 4 or any 3 or any 2 or any 1 of the following CpG sites shown in 9 on the DNA fragment shown in SEQ ID No.4 of the FUT7 gene:
item 1: the CpG site (FUT7_D_2) shown in 56-57 th position of the 5' end of the DNA fragment shown in SEQ ID No. 4;
item 2: the CpG site (FUT7_D_3) shown in 128-129 positions of the DNA fragment shown in SEQ ID No.4 from the 5' end;
Item 3: the CpG site (FUT7_D_4) shown in 211-212 th position of the 5' end of the DNA fragment shown in SEQ ID No. 4;
item 4: the CpG site (FUT7_D_5) shown in 227-228 th position of the DNA fragment shown in SEQ ID No.4 from the 5' end;
item 5: the DNA fragment shown in SEQ ID No.4 shows CpG sites (FUT7_D_6) from 249-250 th position of the 5' end;
item 6: the CpG site (FUT7_D_7) shown in 267-268 of the DNA fragment shown in SEQ ID No.4 from the 5' end;
item 7: the DNA fragment shown in SEQ ID No.4 shows CpG sites (FUT7_D_8) from 348 th to 349 th positions of the 5' end;
item 8: the DNA fragment shown in SEQ ID No.4 shows the CpG site (FUT7_D_9) from 380-381 th position of the 5' end;
item 9: the DNA fragment shown in SEQ ID No.4 shows the CpG sites (FUT7_D_10) from 441 to 442 positions of the 5' end.
In particular embodiments of the invention, some adjacent methylation sites are treated as one methylation site when analyzed for DNA methylation using time-of-flight mass spectrometry, because several CpG sites are located on one methylation fragment, the peak pattern is indistinguishable (indistinguishable sites are set forth in Table 6), and thus the methylation level analysis is performed, and related mathematical models are constructed and used.
The use of the methylation biomarker may be at least one of:
(1) Auxiliary diagnosis of cardiovascular and cerebrovascular diseases or early warning of cardiovascular and cerebrovascular diseases before clinical onset;
(2) Auxiliary diagnosis of coronary heart disease or early warning of coronary heart disease before clinical onset;
(3) Auxiliary diagnosis of cerebral apoplexy or early warning of cerebral apoplexy before clinical onset;
(4) Auxiliary distinguishing coronary heart disease and cerebral apoplexy or early warning and distinguishing coronary heart disease and cerebral apoplexy before clinical onset;
(5) Auxiliary diagnosis of coronary heart disease with different clinical characteristics or early warning of coronary heart disease with different clinical characteristics before clinical onset;
(6) Auxiliary diagnosis of cerebral apoplexy with different clinical characteristics or early warning of cerebral apoplexy with different clinical characteristics before clinical onset;
(7) Auxiliary diagnosis of cardiac injury or early warning of cardiac injury prior to clinical onset;
(8) The cardiovascular and cerebrovascular disease recurrence monitoring is assisted or the cardiovascular and cerebrovascular disease recurrence is early-warned before clinical onset;
(9) Auxiliary coronary heart disease recurrence monitoring or early warning of coronary heart disease recurrence before clinical onset;
(10) Auxiliary cerebral apoplexy recurrence monitoring or cerebral apoplexy recurrence pre-warning before clinical onset;
(11) Auxiliary monitoring of coronary heart disease recurrence with different clinical characteristics or early warning of coronary heart disease recurrence with different clinical characteristics before clinical onset;
(12) Auxiliary monitoring of cerebral apoplexy recurrence with different clinical characteristics or early warning of cerebral recurrence with different clinical characteristics before clinical onset.
Further, the cardiovascular and cerebrovascular diseases described in (1) can be cardiovascular and cerebrovascular diseases such as coronary heart disease and cerebral apoplexy, etc. which can cause the methylation level of FUT7 gene in the organism to be changed.
In the present invention, the auxiliary diagnosis of cardiovascular and cerebrovascular diseases described in (1) may be embodied as at least one of the following: assisting in distinguishing coronary heart disease patients from healthy controls, cerebral apoplexy patients from healthy controls. Wherein, the healthy control can be understood as that no cardiovascular and cerebrovascular diseases or cancers are affected at present and once and no cardiovascular and cerebrovascular diseases are affected in the next 2 years, and the blood routine indexes are all within the reference range. The "healthy control" appearing hereinafter is synonymous.
In the invention, the early warning of cardiovascular and cerebrovascular diseases before clinical onset in (1) is any one of the following: early warning coronary heart disease before clinical onset, early warning cerebral apoplexy before clinical onset, early warning and distinguishing coronary heart disease and cerebral apoplexy before clinical onset.
Further, the testee who early warns of coronary heart disease before clinical onset is a potential patient of coronary heart disease or a healthy control. The potential patients with coronary heart disease are potential patients with coronary heart disease which is happened in the next 2 years or potential patients with coronary heart disease which is happened in the next 1 year (i.e. coronary heart disease can be clinically diagnosed in 2 years or 1 year). The "potential patients for coronary heart disease" appearing hereinafter are synonymous.
Further, the person to be detected who pre-warns of cerebral apoplexy before clinical onset is a potential cerebral apoplexy patient or a healthy control. The potential cerebral apoplexy patient is a potential cerebral apoplexy patient with a future 2 years of onset or a potential cerebral apoplexy patient with a future 1 year of onset (i.e. cerebral apoplexy can be clinically diagnosed within 2 years or within 1 year). The "potential stroke patient" appearing hereinafter is synonymous.
Further, the detected person who early warns and distinguishes coronary heart disease and cerebral apoplexy before clinical onset is a potential patient of coronary heart disease or a potential patient of cerebral apoplexy.
In the present invention, the coronary heart disease of different clinical characteristics described in (5) is: latent or asymptomatic myocardial ischemia, angina, myocardial infarction, ischemic cardiomyopathy or sudden death. The "coronary heart disease of different clinical characteristics" appearing hereinafter is synonymous.
In the present invention, the coronary heart disease of the type described in (5) that assists in diagnosing different clinical characteristics is embodied as at least one of the following: can help to distinguish between patients with latent or asymptomatic myocardial ischemia and healthy controls, can help to distinguish between patients with angina and healthy controls, can help to distinguish between patients with myocardial infarction and healthy controls, can help to distinguish between patients with ischemic myocardial ischemia and healthy controls, can help to distinguish between sudden death and healthy controls. The "diagnosis of coronary heart disease with different clinical features assisted" appearing hereinafter is synonymous.
In the invention, the testees of coronary heart disease with different clinical characteristics, which are early-warned before clinical onset, in the step (5) are coronary heart disease potential patients or healthy controls with different clinical characteristics.
In the present invention, the stroke with different clinical characteristics described in (6) is: ischemic stroke or hemorrhagic stroke. The occurrence of "stroke of different clinical characteristics" hereinafter is synonymous.
In the present invention, the stroke described in (6) that aids in distinguishing different clinical characteristics is embodied as at least one of the following: can help to distinguish ischemic cerebral apoplexy from healthy control, and can help to distinguish ischemic cerebral apoplexy from healthy control. The terms "stroke assisting in differentiating different clinical characteristics" appear synonymously hereinafter.
In the invention, the subjects with pre-alarm of cerebral apoplexy of different clinical characteristics before clinical onset in (6) are potential cerebral apoplexy patients or healthy controls of different clinical characteristics.
In the present invention, the auxiliary diagnosis of cardiac injury described in (7) is embodied as: auxiliary diagnosis of whether heart damage occurs or not a patient with tumor is treated by tumor drugs. The "assisted diagnosis of heart damage" appearing hereinafter is synonymous.
In the invention, the person to be tested who pre-warns of heart injury before clinical onset in (7) is a potential patient with heart injury caused by tumor drug treatment or a patient with heart injury caused by tumor drug treatment.
Further, the potential patient with heart damage caused by the tumor drug treatment is a patient with heart damage in the next 2 years (i.e. a patient with heart damage clinically diagnosed in 2 years) when the tumor patient is treated with the tumor drug. The patient with the tumor, which is not suffered from heart injury after being treated by the tumor drug, is a patient with the tumor, which is not suffered from heart injury in the next 2 years (i.e. the patient with heart injury is not clinically diagnosed in the 2 years).
In a specific embodiment of the invention, the tumor is in particular lung cancer or breast cancer; the drug is specifically doxorubicin, idarubicin and/or epirubicin.
In the invention, the auxiliary cardiovascular and cerebrovascular disease recurrence monitoring in (8) is specifically embodied as any one of the following: and the coronary heart disease recurrence monitoring and the cerebral apoplexy recurrence monitoring are assisted. The "aiding in the monitoring of recurrence of cardiovascular and cerebrovascular diseases" appearing hereinafter is synonymous.
In the invention, the early warning of the recurrence of cardiovascular and cerebrovascular diseases before clinical onset described in (8) is any one of the following: coronary heart disease recurrence is early-warned before clinical onset, and cerebral apoplexy recurrence is early-warned before clinical onset.
Further, the patient to be tested who early warns of the recurrence of the coronary heart disease before the clinical onset is a potential patient with the recurrence of the coronary heart disease (i.e. a patient with the recurrence of the coronary heart disease which is clinically diagnosed within 2 years of prognosis) or a patient without the recurrence of the coronary heart disease. Wherein, the non-recurrent coronary heart disease patient can be understood as the recurrent coronary heart disease patient which is not clinically diagnosed within 2 years of prognosis. The "non-recurrent patient with coronary heart disease" appearing hereinafter is synonymous.
Further, the subject who is to be tested for early warning of the recurrence of the cerebral stroke before the clinical onset is a potential patient for the recurrence of the cerebral stroke (i.e., a patient diagnosed clinically as having the recurrence of the cerebral stroke within 2 years of prognosis) or a non-recurrence patient of the cerebral stroke. Wherein, the cerebral apoplexy non-recurrence patient can be understood as cerebral apoplexy recurrence which is not clinically diagnosed within 2 years after the cerebral apoplexy patient. The term "stroke non-recurrent patient" appearing hereinafter is synonymous.
In the present invention, the recurrence of coronary heart disease of the different clinical characteristics described in (11) is: asymptomatic myocardial ischemia recurrence, angina pectoris recurrence, myocardial infarction recurrence, and ischemic cardiomyopathy. The "recurrence of coronary heart disease with different clinical characteristics" appearing hereinafter is synonymous.
Further, the monitoring of coronary heart disease recurrence as described in (11) in assisting with different clinical characteristics is embodied as at least one of the following: can help to distinguish asymptomatic myocardial ischemia recurrence from asymptomatic myocardial ischemia non-recurrence, can help to distinguish angina pectoris recurrence from angina pectoris non-recurrence, can help to distinguish myocardial infarction recurrence from myocardial infarction non-recurrence, can help to distinguish ischemic cardiomyopathy recurrence from ischemic cardiomyopathy non-recurrence. The following is synonymous with "aiding in the monitoring of recurrence of coronary heart disease with different clinical profiles".
In the present invention, the recurrence of stroke with different clinical features described in (12) is: ischemic stroke recurrence and hemorrhagic stroke recurrence. The occurrence of "stroke recurrence of different clinical characteristics" hereinafter is synonymous.
Further, the monitoring of stroke recurrence as described in (12) to aid in the progression of different clinical characteristics is embodied as at least one of: can help to distinguish the recurrence of ischemic cerebral apoplexy from the non-recurrence of ischemic cerebral apoplexy, and can help to distinguish the recurrence of hemorrhagic cerebral apoplexy from the non-recurrence of hemorrhagic cerebral apoplexy. The following is synonymous with "aiding in the monitoring of recurrence of stroke with different clinical features".
In a second aspect, the invention claims the use of a methylation biomarker as described in the first aspect above in the preparation of a product; the application of the product is at least one of the following:
(1) Auxiliary diagnosis of cardiovascular and cerebrovascular diseases or early warning of cardiovascular and cerebrovascular diseases before clinical onset;
(2) Auxiliary diagnosis of coronary heart disease or early warning of coronary heart disease before clinical onset;
(3) Auxiliary diagnosis of cerebral apoplexy or early warning of cerebral apoplexy before clinical onset;
(4) Auxiliary distinguishing coronary heart disease and cerebral apoplexy or early warning and distinguishing coronary heart disease and cerebral apoplexy before clinical onset;
(5) Auxiliary diagnosis of coronary heart disease with different clinical characteristics or early warning of coronary heart disease with different clinical characteristics before clinical onset;
(6) Auxiliary diagnosis of cerebral apoplexy with different clinical characteristics or early warning of cerebral apoplexy with different clinical characteristics before clinical onset;
(7) Auxiliary diagnosis of cardiac injury or early warning of cardiac injury prior to clinical onset;
(8) The cardiovascular and cerebrovascular disease recurrence monitoring is assisted or the cardiovascular and cerebrovascular disease recurrence is early-warned before clinical onset;
(9) Auxiliary coronary heart disease recurrence monitoring or early warning of coronary heart disease recurrence before clinical onset;
(10) Auxiliary cerebral apoplexy recurrence monitoring or cerebral apoplexy recurrence pre-warning before clinical onset;
(11) Auxiliary monitoring of coronary heart disease recurrence with different clinical characteristics or early warning of coronary heart disease recurrence with different clinical characteristics before clinical onset;
(12) Auxiliary monitoring of cerebral apoplexy recurrence with different clinical characteristics or early warning of cerebral recurrence with different clinical characteristics before clinical onset.
In a third aspect, the invention claims the use of a substance for detecting the methylation level of a methylation biomarker as described in the first aspect above for the preparation of a product; the application of the product is at least one of the following:
(1) Auxiliary diagnosis of cardiovascular and cerebrovascular diseases or early warning of cardiovascular and cerebrovascular diseases before clinical onset;
(2) Auxiliary diagnosis of coronary heart disease or early warning of coronary heart disease before clinical onset;
(3) Auxiliary diagnosis of cerebral apoplexy or early warning of cerebral apoplexy before clinical onset;
(4) Auxiliary distinguishing coronary heart disease and cerebral apoplexy or early warning and distinguishing coronary heart disease and cerebral apoplexy before clinical onset;
(5) Auxiliary diagnosis of coronary heart disease with different clinical characteristics or early warning of coronary heart disease with different clinical characteristics before clinical onset;
(6) Auxiliary diagnosis of cerebral apoplexy with different clinical characteristics or early warning of cerebral apoplexy with different clinical characteristics before clinical onset;
(7) Auxiliary diagnosis of cardiac injury or early warning of cardiac injury prior to clinical onset;
(8) The cardiovascular and cerebrovascular disease recurrence monitoring is assisted or the cardiovascular and cerebrovascular disease recurrence is early-warned before clinical onset;
(9) Auxiliary coronary heart disease recurrence monitoring or early warning of coronary heart disease recurrence before clinical onset;
(10) Auxiliary cerebral apoplexy recurrence monitoring or cerebral apoplexy recurrence pre-warning before clinical onset;
(11) Auxiliary monitoring of coronary heart disease recurrence with different clinical characteristics or early warning of coronary heart disease recurrence with different clinical characteristics before clinical onset;
(12) Auxiliary monitoring of cerebral apoplexy recurrence with different clinical characteristics or early warning of cerebral recurrence with different clinical characteristics before clinical onset.
In a fourth aspect, the invention claims the use of a substance for detecting the methylation level of a methylation biomarker as described in the first aspect above and a medium storing a mathematical model and/or a method of using a mathematical model for the preparation of a product; the application of the product is at least one of the following:
(1) Auxiliary diagnosis of cardiovascular and cerebrovascular diseases or early warning of cardiovascular and cerebrovascular diseases before clinical onset;
(2) Auxiliary diagnosis of coronary heart disease or early warning of coronary heart disease before clinical onset;
(3) Auxiliary diagnosis of cerebral apoplexy or early warning of cerebral apoplexy before clinical onset;
(4) Auxiliary distinguishing coronary heart disease and cerebral apoplexy or early warning and distinguishing coronary heart disease and cerebral apoplexy before clinical onset;
(5) Auxiliary diagnosis of coronary heart disease with different clinical characteristics or early warning of coronary heart disease with different clinical characteristics before clinical onset;
(6) Auxiliary diagnosis of cerebral apoplexy with different clinical characteristics or early warning of cerebral apoplexy with different clinical characteristics before clinical onset;
(7) Auxiliary evaluation of cardiac injury of tumor patients caused by tumor drug treatment;
(7) Auxiliary diagnosis of cardiac injury or early warning of cardiac injury prior to clinical onset;
(8) The cardiovascular and cerebrovascular disease recurrence monitoring is assisted or the cardiovascular and cerebrovascular disease recurrence is early-warned before clinical onset;
(9) Auxiliary coronary heart disease recurrence monitoring or early warning of coronary heart disease recurrence before clinical onset;
(10) Auxiliary cerebral apoplexy recurrence monitoring or cerebral apoplexy recurrence pre-warning before clinical onset;
(11) Auxiliary monitoring of coronary heart disease recurrence with different clinical characteristics or early warning of coronary heart disease recurrence with different clinical characteristics before clinical onset;
(12) Auxiliary monitoring of cerebral apoplexy recurrence with different clinical characteristics or early warning of cerebral recurrence with different clinical characteristics before clinical onset.
The mathematical model is obtained according to a method comprising the following steps:
(A1) Detecting the methylation level of the methylation biomarker of claim 1 of n1 type a samples and n2 type B samples, respectively;
(A2) Taking methylation level data of the methylation biomarkers of claim 1 of all samples obtained in the step (A1), and establishing a mathematical model by a two-classification logistic regression method according to classification modes of A type and B type;
wherein, n1 and n2 can be positive integers more than 10.
The using method of the mathematical model comprises the following steps:
(B1) Detecting the methylation level of the methylation biomarker of claim 1 in a test sample;
(B2) Substituting methylation level data of the methylation biomarker of claim 1 of the sample to be tested obtained in the step (B1) into the mathematical model to obtain a detection index; and then comparing the detection index with a threshold value, and determining whether the type of the sample to be detected is A type or B type according to the comparison result.
In a specific embodiment of the present invention, the threshold is set to 0.5. More than 0.5 is classified as one type, less than 0.5 is classified as another type, and 0.5 is equal as an undefined gray zone. Wherein the A type and the B type are two corresponding classifications, the two classifications are grouped, which group is the A type and which group is the B type, and the A type and the B type are determined according to a specific mathematical model without convention.
In practical applications, the threshold may also be determined according to the maximum approximate sign-up index (specifically, may be a value corresponding to the maximum approximate sign-up index). Greater than the threshold is classified as one class, less than the threshold is classified as another class, and equal to the threshold as an indeterminate gray zone. Wherein the A type and the B type are two corresponding classifications, the two classifications are grouped, which group is the A type and which group is the B type, and the A type and the B type are determined according to a specific mathematical model without convention.
The type a sample and the type B sample are any one of the following:
(C1) Potential patients with coronary heart disease and healthy controls for onset within the next 2 years;
(C2) Potential patients with stroke and healthy controls that developed within the next 2 years;
(C3) Coronary heart disease potential patients with onset in the next 2 years and cerebral apoplexy potential patients with onset in the next 2 years;
(C4) Coronary heart disease potential patients and healthy controls with different clinical characteristics of onset within the next 2 years;
(C5) Stroke potential patients and healthy controls of different clinical characteristics of onset within the next 2 years;
(C6) Potential patients with coronary heart disease and healthy controls for onset within the next 1 year;
(C7) Potential patients with stroke and healthy controls that developed within the next 1 year;
(C8) Coronary heart disease potential patients with onset in the next 1 year and cerebral apoplexy potential patients with onset in the next 1 year;
(C9) Coronary heart disease potential patients and healthy controls with different clinical characteristics of onset within the next 1 year;
(C10) Stroke potential patients and healthy controls of different clinical characteristics of the onset within the next 1 year;
(C11) Patients with and without heart injury due to treatment with tumor drugs in the next 2 years;
(C12) Patients with recurrent cardiovascular and cerebrovascular diseases and non-recurrent patients within 2 years of prognosis;
(C13) Coronary heart disease recurrent patients and non-recurrent patients within 2 years of prognosis;
(C14) Stroke relapsing patients and non-relapsing patients within 2 years of prognosis;
(C15) Coronary heart disease recurrent patients and non-recurrent patients with different clinical characteristics within 2 years of prognosis;
(C16) Cerebral stroke relapsing patients and non-relapsing patients with different clinical characteristics within 2 years of prognosis.
In a fifth aspect, the invention claims a kit.
The kit as claimed in the present invention comprises a substance for detecting the methylation level of the methylation biomarker described in the first aspect hereinbefore; the use of the kit may be at least one of the following:
(1) Auxiliary diagnosis of cardiovascular and cerebrovascular diseases or early warning of cardiovascular and cerebrovascular diseases before clinical onset;
(2) Auxiliary diagnosis of coronary heart disease or early warning of coronary heart disease before clinical onset;
(3) Auxiliary diagnosis of cerebral apoplexy or early warning of cerebral apoplexy before clinical onset;
(4) Auxiliary distinguishing coronary heart disease and cerebral apoplexy or early warning and distinguishing coronary heart disease and cerebral apoplexy before clinical onset;
(5) Auxiliary diagnosis of coronary heart disease with different clinical characteristics or early warning of coronary heart disease with different clinical characteristics before clinical onset;
(6) Auxiliary diagnosis of cerebral apoplexy with different clinical characteristics or early warning of cerebral apoplexy with different clinical characteristics before clinical onset;
(7) Auxiliary diagnosis of cardiac injury or early warning of cardiac injury prior to clinical onset;
(8) The cardiovascular and cerebrovascular disease recurrence monitoring is assisted or the cardiovascular and cerebrovascular disease recurrence is early-warned before clinical onset;
(9) Auxiliary coronary heart disease recurrence monitoring or early warning of coronary heart disease recurrence before clinical onset;
(10) Auxiliary cerebral apoplexy recurrence monitoring or cerebral apoplexy recurrence pre-warning before clinical onset;
(11) Auxiliary monitoring of coronary heart disease recurrence with different clinical characteristics or early warning of coronary heart disease recurrence with different clinical characteristics before clinical onset;
(12) Auxiliary monitoring of cerebral apoplexy recurrence with different clinical characteristics or early warning of cerebral recurrence with different clinical characteristics before clinical onset.
Further, the kit may further comprise a medium storing a mathematical model and/or a method for using a mathematical model as described in the fourth aspect.
In a sixth aspect, the invention claims a system.
The system claimed in the present invention may include:
(D1) Reagents and/or instrumentation for detecting the methylation level of the methylation biomarker described in the first aspect hereinbefore;
(D2) A device comprising a unit X and a unit Y;
the unit X is used for establishing a mathematical model and comprises a data acquisition module, a data analysis processing module and a model output module;
the data acquisition module is configured to acquire (D1) methylation level data of the methylation biomarker of claim 1 of n1 type a samples and n2 type B samples detected;
the data analysis processing module is configured to receive methylation level data of the methylation biomarker of the claim 1 from n1 type A samples and n2 type B samples sent by the data acquisition module, and establish a mathematical model through a two-classification logistic regression method according to classification modes of the type A and the type B to determine a threshold value of classification judgment;
wherein, n1 and n2 can be positive integers more than 10.
The model output module is configured to receive the mathematical model sent by the data analysis processing module and output the mathematical model;
the unit Y is used for determining the type of the sample to be detected and comprises a data input module, a data operation module, a data comparison module and a conclusion output module;
the data input module is configured to input (D1) the methylation level data of the methylation biomarker in the previous first aspect of the tested person detected;
the data operation module is configured to receive methylation level data of the methylation biomarker in the first aspect of the person to be tested, sent by the data input module, and substitute the methylation level data of the methylation biomarker in the first aspect of the person to be tested into the mathematical model to calculate a detection index;
the data comparison module is configured to receive the detection index sent from the data operation module and compare the detection index with the threshold value determined in the data analysis processing module in the unit X;
the conclusion output module is configured to receive the comparison result sent by the data comparison module and output a conclusion of whether the type of the sample to be tested is A type or B type according to the comparison result;
The type a sample and the type B sample are any one of the following:
(C1) Potential patients with coronary heart disease and healthy controls for onset within the next 2 years;
(C2) Potential patients with stroke and healthy controls that developed within the next 2 years;
(C3) Coronary heart disease potential patients with onset in the next 2 years and cerebral apoplexy potential patients with onset in the next 2 years;
(C4) Coronary heart disease potential patients and healthy controls with different clinical characteristics of onset within the next 2 years;
(C5) Stroke potential patients and healthy controls of different clinical characteristics of onset within the next 2 years;
(C6) Potential patients with coronary heart disease and healthy controls for onset within the next 1 year;
(C7) Potential patients with stroke and healthy controls that developed within the next 1 year;
(C8) Coronary heart disease potential patients with onset in the next 1 year and cerebral apoplexy potential patients with onset in the next 1 year;
(C9) Coronary heart disease potential patients and healthy controls with different clinical characteristics of onset within the next 1 year;
(C10) Stroke potential patients and healthy controls of different clinical characteristics of the onset within the next 1 year;
(C11) Patients with and without heart injury due to treatment with tumor drugs in the next 2 years;
(C12) Patients with recurrent cardiovascular and cerebrovascular diseases and non-recurrent patients within 2 years of prognosis;
(C13) Coronary heart disease recurrent patients and non-recurrent patients within 2 years of prognosis;
(C14) Stroke relapsing patients and non-relapsing patients within 2 years of prognosis;
(C15) Coronary heart disease recurrent patients and non-recurrent patients with different clinical characteristics within 2 years of prognosis;
(C16) Cerebral stroke relapsing patients and non-relapsing patients with different clinical characteristics within 2 years of prognosis.
In a specific embodiment of the present invention, the threshold is set to 0.5. More than 0.5 is classified as one type, less than 0.5 is classified as another type, and 0.5 is equal as an undefined gray zone. Wherein the A type and the B type are two corresponding classifications, the two classifications are grouped, which group is the A type and which group is the B type, and the A type and the B type are determined according to a specific mathematical model without convention.
In practical applications, the threshold may also be determined according to the maximum approximate sign-up index (specifically, may be a value corresponding to the maximum approximate sign-up index). Greater than the threshold is classified as one class, less than the threshold is classified as another class, and equal to the threshold as an indeterminate gray zone. Wherein the A type and the B type are two corresponding classifications, the two classifications are grouped, which group is the A type and which group is the B type, and the A type and the B type are determined according to a specific mathematical model without convention.
In the foregoing aspects, the period of time before clinical onset may be specifically within 2 years of the period of time before clinical onset or within 1 year of the period of time before clinical onset or within 2 years of recurrence of the clinical condition. The potential coronary heart disease patients with the onset within 2 years (or within 1 year) in the future are the potential coronary heart disease patients which are found within 2 years (or within 1 year) earlier than the clinical onset time; the potential cerebral apoplexy patients with the future 2 years (or 1 year) are the potential cerebral apoplexy patients which are found 2 years (or 1 year) earlier than the clinical onset time. The patient diagnosed with heart damage within the next 2 years from receiving oncological drug therapy may be a patient diagnosed with heart damage within 2 years of the clinical onset time. The coronary heart disease patient with recurrence within 2 years is earlier than the clinical coronary heart disease recurrence time within 2 years. The cerebral apoplexy patient with recurrence within 2 years of prognosis is earlier than the clinical cerebral apoplexy recurrence time within 2 years.
In each of the above aspects, the substance for detecting the methylation level of the methylation biomarker described in the first aspect above comprises (or is) primer pair a and/or primer pair B and/or primer pair C and/or primer pair D.
The primer pair A is a primer pair consisting of a primer A1 and a primer A2; the primer A1 is SEQ ID No.5 or single-stranded DNA shown in 11 th-35 th nucleotides of SEQ ID No. 5; the primer A2 is SEQ ID No.6 or single-stranded DNA shown in 32 th-56 th nucleotides of SEQ ID No. 6;
the primer pair B is a primer pair consisting of a primer B1 and a primer B2; the primer B1 is SEQ ID No.7 or single-stranded DNA shown in 11 th-35 th nucleotides of SEQ ID No. 7; the primer B2 is single-stranded DNA shown in SEQ ID No.8 or 32-56 nucleotides of SEQ ID No. 8;
the primer pair C is a primer pair consisting of a primer C1 and a primer C2; the primer C1 is SEQ ID No.9 or single-stranded DNA shown in 11 th-35 th nucleotides of SEQ ID No. 9; the primer C2 is SEQ ID No.10 or single-stranded DNA shown in 32 th-56 th nucleotides of SEQ ID No. 10;
the primer pair D is a primer pair consisting of a primer D1 and a primer D2; the primer D1 is SEQ ID No.11 or single-stranded DNA shown in 11 th-35 th nucleotides of SEQ ID No. 11; the primer D2 is SEQ ID No.12 or single-stranded DNA shown in 32-56 nucleotides of SEQ ID No. 12.
In the above aspects, the apparatus for detecting the methylation level of the methylation biomarker described in the first aspect above may be a time-of-flight mass spectrometry detector. Of course other conventional reagents for performing time-of-flight mass spectrometry may also be included in the reagents for detecting the methylation level of the methylation biomarkers described in the first aspect hereinbefore.
In addition, the invention also discloses a method for distinguishing whether the sample to be detected is an A type sample or a B type sample. The method may comprise the steps of:
(A) The mathematical model may be built as a method comprising the steps of:
(A1) Detecting methylation levels of the methylation biomarkers described in the foregoing first aspect of n1 type a samples and n2 type B samples, respectively (training set);
(A2) Taking methylation level data of the methylation biomarkers in the first aspect of all samples obtained in the step (A1), establishing a mathematical model according to classification modes of A type and B type by a two-classification logistic regression method, and determining a threshold value of classification judgment.
Wherein, n1 and n2 in (A1) can be positive integers more than 10.
(B) The sample to be tested may be determined as a type a sample or a type B sample according to a method comprising the steps of:
(B1) Detecting the methylation level of the methylation biomarker in the first aspect above of the test sample;
(B2) Substituting methylation level data of the methylation biomarker in the first aspect of the sample to be tested obtained in the step (B1) into the mathematical model to obtain a detection index; and then comparing the detection index with a threshold value, and determining whether the type of the sample to be detected is A type or B type according to the comparison result.
In a specific embodiment of the present invention, the threshold is set to 0.5. More than 0.5 is classified as one type, less than 0.5 is classified as another type, and 0.5 is equal as an undefined gray zone. Wherein the A type and the B type are two corresponding classifications, the two classifications are grouped, which group is the A type and which group is the B type, and the A type and the B type are determined according to a specific mathematical model without convention.
In practical applications, the threshold may also be determined according to the maximum approximate sign-up index (specifically, may be a value corresponding to the maximum approximate sign-up index). Greater than the threshold is classified as one class, less than the threshold is classified as another class, and equal to the threshold as an indeterminate gray zone. Wherein the A type and the B type are two corresponding classifications, the two classifications are grouped, which group is the A type and which group is the B type, and the A type and the B type are determined according to a specific mathematical model without convention.
The type a sample and the type B sample are any one of:
(C1) Potential patients with coronary heart disease and healthy controls for onset within the next 2 years;
(C2) Potential patients with stroke and healthy controls that developed within the next 2 years;
(C3) Coronary heart disease potential patients with onset in the next 2 years and cerebral apoplexy potential patients with onset in the next 2 years;
(C4) Coronary heart disease potential patients and healthy controls with different clinical characteristics of onset within the next 2 years;
(C5) Stroke potential patients and healthy controls of different clinical characteristics of onset within the next 2 years;
(C6) Potential patients with coronary heart disease and healthy controls for onset within the next 1 year;
(C7) Potential patients with stroke and healthy controls that developed within the next 1 year;
(C8) Coronary heart disease potential patients with onset in the next 1 year and cerebral apoplexy potential patients with onset in the next 1 year;
(C9) Coronary heart disease potential patients and healthy controls with different clinical characteristics of onset within the next 1 year;
(C10) Stroke potential patients and healthy controls of different clinical characteristics of the onset within the next 1 year;
(C11) Patients with and without heart injury due to treatment with tumor drugs in the next 2 years;
(C12) Patients with recurrent cardiovascular and cerebrovascular diseases and non-recurrent patients within 2 years of prognosis;
(C13) Coronary heart disease recurrent patients and non-recurrent patients within 2 years of prognosis;
(C14) Stroke relapsing patients and non-relapsing patients within 2 years of prognosis;
(C15) Coronary heart disease recurrent patients and non-recurrent patients with different clinical characteristics within 2 years of prognosis;
(C16) Cerebral stroke relapsing patients and non-relapsing patients with different clinical characteristics within 2 years of prognosis.
In practical applications, any of the above mathematical models may be changed according to the detection method and the fitting method of DNA methylation, and the mathematical model is determined according to a specific mathematical model without any convention.
In the embodiment of the invention, the model is specifically log (y/(1-y))=b0+b1x1+b2x2+b3x3+ … +bnxn, where y is a detection index obtained after substituting a methylation value of one or more methylation sites of a sample to be tested into the model as a dependent variable, b0 is a constant, x1-xn is an independent variable which is a methylation value of one or more methylation sites of the sample to be tested (each value is a value between 0 and 1), and b1-bn is a weight given by the model to the methylation value of each site.
In the embodiment of the invention, the model can be established by adding known parameters such as age, sex, white blood cell count and the like as appropriate to improve the discrimination efficiency. Five specific models established in the embodiment of the invention are used for assisting in distinguishing potential cardiovascular and cerebrovascular disease patients (coronary heart disease and cerebral apoplexy) with the onset within 2 years from healthy controls, heart damage and no heart damage caused by the treatment of tumor medicaments within the next 2 years, recurrence and non-recurrence of coronary heart disease within the next 2 years and recurrence and non-recurrence of cerebral apoplexy within the next 2 years. The model one is specifically as follows: log (y/(1-y)) = -0.504+2.569 x fut7_d_2+1.556 x fut7_d_3-6.395 x fut7_d_4-1.238 x fut7_d_5+6.379 x fut7_d_6-1.345 x fut7_d_7+6.922 x fut7_d_8-2.943 x fut7_d_9-2.701 x fut7_d_10-0.028 x age (integer) +0.169 x sex (male assignment 1, female assignment 0) -0.014 x white blood cell number (unit 10) 9 /L). Wherein y is a detection index obtained by substituting the methylation values of 9 distinguishable methylation sites of the sample to be detected into the model and converting the methylation values into age, sex and white blood cell count. The threshold for model one is 0.5. Patient candidates with a detection index greater than 0.5 calculated by the model were potential coronary heart disease patients with onset within 2 years, and patient candidates less than 0.5 were healthy controls. The second model is specifically as follows: log (y/(1-y)) = -1.694+1.138 fut7_d_2+3.708 fut7_d_3+4.525 fut7_d_4-0.789 fut7_d_5-7.505 fut7_d_6-1.675 fut7_d_7-2.836 fut7_d_8-3.825 fut7_d_9-1.301 fut7_d_10+0.013 age (integer) 0.159 sex (male assigned 1, female assigned 0) +0.096 white blood cell number (unit 10) 9 L), wherein y is the detection index obtained by conversion after substituting the methylation values of 9 distinguishable methylation sites of the sample to be tested and the age, sex and white blood cell count into the model. The threshold of the second model is 0.5. Patient candidates with detection indices greater than 0.5 calculated by the model are ill within 2 yearsLess than 0.5 patient candidates were healthy controls. The model three is specifically as follows: log (y/(1-y))=2.756-0.948×fut7_d_2+1.325×fut7_d_3-0.195×fut7_d_4-0.990×fut7_d_5+4.481×fut7_d_6-3.009×fut7_d_7+0.113×fut7_d_8-1.491×fut7_d_9+1.595×fut7_d_10-0.064×age (integer) +0.193×sex (male assigned 1, female assigned 0) +0.107×white blood cell number (unit 10) 9 /L). Wherein y is a detection index obtained by substituting a dependent variable, namely, methylation values of 10 distinguishable methylation sites of a sample to be detected, and age, sex and white blood cell count into a model and then converting the methylation values. The threshold for model three was 0.5. Patient candidates with a detection index calculated by the model of greater than 0.5 are patients with heart damage within 2 years after treatment with a tumor drug, and patient candidates with less than 0.5 are patients with no heart damage within 2 years after treatment with a tumor drug. The model IV specifically comprises: log (y/(1-y)) = -3.702+0.897 x fut7_d_2-0.519 x fut7_d_3+1.418 x fut7_d_4+0.876 x fut7_d_5-5.421 x fut7_d_6+1.982 x fut7_d_7+1.116 x fut7_d_8+1.714 x fut7_d_9-0.279 x fut7_d_10-0.095 x age (integer) +0.202 x sex (male assignment 1, female assignment 0) +0.058 x white blood cell number (unit 10) 9 /L). Wherein y is a detection index obtained by substituting a dependent variable, namely, methylation values of 10 distinguishable methylation sites of a sample to be detected, and age, sex and white blood cell count into a model and then converting the methylation values. The threshold for model four is 0.5. Patient candidates with a detection index greater than 0.5 calculated by the model were patients with recurrent coronary heart disease within 2 years of prognosis, and patient candidates with less than 0.5 were patients with non-recurrent coronary heart disease within 2 years of prognosis. The model five is specifically as follows: log (y/(1-y)) = -4.473+2.056-fut7_d_2-1.926-fut7_d_3+2.704-fut7_d_4-0.503-fut7_d_5-1.493-fut7_d_6+0.893-fut7_d_7-0.158-fut7_d_8-2.649-fut7_d_9+1.603-fut7_d_10+0.074-age (integer) -0.449-sex (male assignment 1, female assignment 0) +0.030-white blood cell number (unit 10) 9 /L). Wherein y is a detection index obtained by substituting a dependent variable, namely, methylation values of 10 distinguishable methylation sites of a sample to be detected, and age, sex and white blood cell count into a model and then converting the methylation values. The threshold for model five was 0.5. Patient candidates with detection indices greater than 0.5 calculated by the modelFor a patient with a recurrence of stroke within 2 years of prognosis, less than 0.5 patient candidates are those with a non-recurrence of stroke within 2 years of prognosis. In the first to fifth models, the FUT7_D_2 is the methylation level of the CpG site shown in 56-57 th position of the 5' end of the DNA fragment shown in SEQ ID No. 4; the FUT7_D_3 is the methylation level of CpG sites shown in the 128 th-129 th position of the 5' end of the DNA fragment shown in SEQ ID No. 4; the FUT7_D_4 is the methylation level of CpG sites shown in the 211-212 th position of the 5' end of the DNA fragment shown in SEQ ID No. 4; the FUT7_D_5 is the methylation level of CpG sites shown in 227-228 th positions of a DNA fragment shown in SEQ ID No.4 from the 5' end; the FUT7_D_6 is the methylation level of CpG sites shown in the 249-250 th position of the 5' end of the DNA fragment shown in SEQ ID No. 4; the FUT7_D_7 is the methylation level of CpG sites shown in 267-268 positions of the DNA fragment shown in SEQ ID No.4 from the 5' end; the FUT7_D_8 is the methylation level of CpG sites shown in the 348 th to 349 th positions of the 5' end of the DNA fragment shown in SEQ ID No. 4; the FUT7_D_9 is the methylation level of CpG sites shown in 380-381 th position of the 5' end of the DNA fragment shown in SEQ ID No. 4; the FUT7_D_10 is the methylation level of CpG sites shown in the 441 th to 442 th positions of the 5' end of the DNA fragment shown in SEQ ID No. 4.
In the above aspects, detecting the methylation level of the methylation biomarker of the first aspect of the present disclosure is detecting the methylation level of the methylation biomarker of the first aspect of the present disclosure in a blood sample. I.e. the sample to be measured is a blood sample.
Any of the above genes specifically may include Genbank accession No.: NM-004479.4, transcript variant 1.
The invention provides hypermethylation of FUT7 gene in blood of coronary heart disease patient and hypomethylation of FUT7 gene in blood of cerebral apoplexy patient. Experiments prove that the blood can be used as a sample to early warn and distinguish cardiovascular and cerebrovascular diseases (coronary heart disease and cerebral apoplexy) and healthy controls before clinical onset, to early warn and distinguish coronary heart disease patients with different clinical characteristics and healthy controls before clinical onset, and to early warn and distinguish cerebral apoplexy patients with different clinical characteristics and healthy controls before clinical onset. The invention has important scientific significance and clinical application value for improving the early diagnosis and treatment effect of cardiovascular and cerebrovascular diseases and reducing the death rate.
Drawings
FIG. 1 is a schematic diagram of a mathematical model.
Fig. 2 is an illustration of a mathematical model of coronary heart disease.
Fig. 3 is an illustration of a mathematical model of cerebral apoplexy.
Detailed Description
The following detailed description of the invention is provided in connection with the accompanying drawings that are presented to illustrate the invention and not to limit the scope thereof. The examples provided below are intended as guidelines for further modifications by one of ordinary skill in the art and are not to be construed as limiting the invention in any way.
The experimental methods in the following examples, unless otherwise specified, are conventional methods, and are carried out according to techniques or conditions described in the literature in the field or according to the product specifications. Materials, reagents and the like used in the examples described below are commercially available unless otherwise specified.
The quantitative test of the N-Fucosyltransferase VII (FUT 7) gene in the following examples was performed in three replicates, and the results were averaged.
Example 1 primer design for detection of methylation site of Gene
Four fragments (fut7_a fragment, fut7_b fragment, fut7_c fragment, fut7_d fragment) of the gene were selected for methylation level and cardiovascular and cerebrovascular disease correlation analysis through a number of sequence and functional analyses.
The FUT7_A fragment (SEQ ID No. 1) is located on the antisense strand of the hg19 reference genome chr9: 139925180-139926021.
The FUT7_B fragment (SEQ ID No. 2) is located on the antisense strand of the hg19 reference genome chr9: 139926028-139926642.
The FUT7_C fragment (SEQ ID No. 3) is located on the antisense strand of the hg19 reference genome chr9: 139926642-139927156.
The FUT7_D fragment (SEQ ID No. 4) is located on the antisense strand of the hg19 reference genome chr9: 139927156-139927873.
CpG site information in the FUT7_A fragment is shown in Table 1.
CpG site information in the FUT7_B fragment is shown in Table 2.
CpG site information in the FUT7_C fragment is shown in Table 3.
CpG site information in the FUT7_D fragment is shown in Table 4.
Table 1 CpG site information in FUT7_A fragment
Table 2 CpG site information in FUT7_B fragment
Table 3 CpG site information in FUT 7C fragment
Table 4 CpG site information in FUT7_D fragment
| CpG sites | Position of CpG sites in the sequence |
| FUT7_D_1 | SEQ ID No.4 from positions 26-27 of the 5' end |
| FUT7_D_2 | SEQ ID No.4 from position 56-57 of the 5' end |
| FUT7_D_3 | SEQ ID No.4 from position 128-129 of the 5' end |
| FUT7_D_4 | SEQ ID No.4 from position 211-212 of the 5' end |
| FUT7_D_5 | SEQ ID No.4 from position 227 to 228 on the 5' end |
| FUT7_D_6 | SEQ ID No.4 from positions 249-250 of the 5' end |
| FUT7_D_7 | SEQ ID No.4 from position 267-268 of the 5' end |
| FUT7_D_8 | SEQ ID No.4 from position 348 to 349 of the 5' end |
| FUT7_D_9 | SEQ ID No.4 from positions 380-381 of the 5' end |
| FUT7_D_10 | From position 441-442 of the 5' end of SEQ ID No.4 |
| FUT7_D_11 | 485 th to 486 th positions of SEQ ID No.4 from 5' end |
| FUT7_D_12 | SEQ ID No.4 from positions 504-505 of the 5' end |
| FUT7_D_13 | SEQ ID No.4 from position 510-511 of the 5' end |
| FUT7_D_14 | SEQ ID No.4 from positions 603-604 of the 5' end |
| FUT7_D_15 | SEQ ID No.4 from position 628 to 629 of the 5' end |
| FUT7_D_16 | SEQ ID No.4 from positions 668-669 of the 5' end |
| FUT7_D_17 | SEQ ID No.4 shows 690-691 th position from 5' end |
| FUT7_D_18 | 692 th to 693 rd positions of SEQ ID No.4 from 5' end |
Specific PCR primers were designed for three fragments (FUT7_A fragment, FUT7_B fragment, FUT7_C fragment, FUT7_D fragment) as shown in Table 5. Wherein SEQ ID No.5, SEQ ID No.7, SEQ ID No.9 and SEQ ID No.11 are forward primers, and SEQ ID No.6, SEQ ID No.8, SEQ ID No.10 and SEQ ID No.12 are reverse primers; non-specific tags are arranged at positions 1 to 10 from 5' in SEQ ID No.5, SEQ ID No.7, SEQ ID No.9 and SEQ ID No.11, and specific primer sequences are arranged at positions 11 to 35; the non-specific tags are located at positions 1 to 31 from 5' in SEQ ID No.6, SEQ ID No.8, SEQ ID No.10 and SEQ ID No.12, and the specific primer sequences are located at positions 32 to 56. The primer sequences do not contain SNPs and CpG sites.
TABLE 5 methylation primer sequences
Example 2 Gene methylation detection and analysis of results
1. Study sample
1. Research sample for assisting early screening of cardiovascular and cerebrovascular diseases
The research sample adopts an epidemiological whole group sampling method, and the follow-up investigation is carried out on community groups over 18 years old in a certain city for more than 2 years. The study was reviewed by the ethics committee and all panelists signed informed consent. Cardiovascular and cerebrovascular diseases and cancer incidence information are recorded annually through local hospitals, disease control center chronic disease management systems, community health service centers and workstation chronic disease routine registration projects and social security center reimbursement data. The starting time of the queue is the baseline investigation date, the ending variable is the cardiovascular and cerebrovascular diseases, and the follow-up time of the study subjects without visit is uniformly calculated according to half of the follow-up ending time.
The expiration date is 7 months in 2018, and the total cardiovascular and cerebrovascular diseases are 620 people, and the invention selects a queue
The new cardiovascular and cerebrovascular disease patients within 2 years after the group is taken as a case group, wherein 342 cases are coronary heart disease patients, and 278 cases are cerebral apoplexy patients. After age and sex matching, the population without cardiovascular and cerebrovascular diseases and cancers in the follow-up period (the follow-up time is more than 2 years) and with blood routine indexes in the reference range is selected as a control, and 612 cases are counted.
All patient ex vivo blood samples were collected prior to onset. The disease condition is confirmed by imaging and pathology in the subsequent disease.
342 patients suffering from coronary heart disease within 2 years after the group are classified according to clinical typing: 45 cases of latent or asymptomatic myocardial ischemia, 64 cases of angina pectoris, 83 cases of myocardial infarction, 74 cases of ischemic cardiomyopathy and 76 cases of sudden death. Wherein 137 cases of coronary heart disease occur within 1 year after the administration, including 20 cases of latent or asymptomatic myocardial ischemia, 21 cases of angina pectoris, 33 cases of myocardial infarction, 30 cases of ischemic cardiomyopathy and 33 cases of sudden death.
278 patients suffering from cerebral apoplexy within 2 years after group entry are classified according to clinical typing: 112 cases of cerebral arterial thrombosis and 166 cases of cerebral arterial thrombosis. Of these, 110 cases developed cerebral apoplexy within 1 year after the group, including 49 cases of hemorrhagic cerebral apoplexy and 61 cases of ischemic cerebral apoplexy.
Healthy controls had a median age of 65 years, patients with coronary heart disease and stroke who developed within 2 years of the group had median ages of 64 and 65 years, respectively, and the ratio of men to women in each of these 3 groups was about 1:1. Median age of patients suffering from coronary heart disease and cerebral apoplexy within 1 year after the administration is 65 and 64 years, respectively, and the ratio of men and women in the group is about 1:1.
2. Research sample for assisting in diagnosing cardiac injury condition of tumor patient after drug administration
The study selects two tumor patient groups of lung cancer and breast cancer as follow-up targets, and the taken tumor drugs are doxorubicin, idarubicin and/or epirubicin.
After age and sex matching, a total of 147 patients and 105 patients without heart injury in 2 years during the selected follow-up period (the follow-up time is longer than 2 years) due to receiving the tumor treatment drug.
All patient ex vivo blood samples were collected before cardiac injury occurred after tumor drug administration. The disease condition is confirmed by imaging and pathology in the subsequent disease.
The median ages of the patients who developed cardiac injury and did not develop cardiac injury within 2 years after the group were 65 and 63 years, respectively, and the ratio of men and women in each of these 2 groups was about 1:1.
3. Research sample for auxiliary diagnosis of cardiovascular and cerebrovascular prognosis evaluation
The research sample adopts an epidemiological whole group sampling method, and carries out follow-up investigation on community groups over 18 years old in a certain city for more than 2 years, wherein the follow-up time is 2016 years 2 months to 2018 years 7 months. Recurrent cardiovascular and cerebrovascular disease information is recorded in local hospitals, chronic disease management systems of disease control centers, community health service centers and common registration projects of chronic diseases of workstations and reimbursement data of social security centers. The starting time of the queue is the baseline investigation date, and the ending variable is the recurrence of cardiovascular and cerebrovascular diseases. For the follow-up time of the study subjects, the follow-up time is uniformly calculated according to half of the follow-up end time. And after the end of the follow-up visit, counting 216 recurrent cardiovascular and cerebrovascular diseases as a case group, wherein 118 recurrent coronary heart disease patients and 98 recurrent cerebral apoplexy patients. After age and sex matching, the population which does not have cardiovascular diseases and does not relapse within 2 years (the follow-up time is longer than 2 years) and has blood routine indexes within the reference range is selected as a control, and 286 cases are taken as a total, wherein 165 cases of coronary heart diseases and 121 cases of cerebral apoplexy are taken as the control.
All patient ex vivo blood samples were collected prior to disease recurrence. The disease recurrence is confirmed by imaging and pathology at the time of subsequent onset.
118 patients with recurrence of coronary heart disease within 2 years after group entry were classified according to clinical typing: 25 cases of latent or asymptomatic myocardial ischemia, 26 cases of angina pectoris, 35 cases of myocardial infarction and 32 cases of ischemic cardiomyopathy.
98 patients with recurrence of cerebral stroke within 2 years after group entry were classified according to clinical typing: 42 cases of cerebral arterial thrombosis and 56 cases of cerebral arterial thrombosis.
The median age of the cardiovascular and cerebrovascular non-recurrence is 64 years, the median of the ages of the patients suffering from coronary heart disease recurrence and the patients suffering from cerebral apoplexy recurrence within 2 years after the patients are respectively 65 and 66 years, and the ratio of men and women in the groups is about 1:1.
2. Methylation detection
1. Total DNA of the blood sample is extracted.
2. The total DNA of the blood samples prepared in step 1 was subjected to bisulfite treatment (see DNA methylation kit instructions for Qiagen). After bisulfite treatment, unmethylated cytosines (C) in the original CpG sites are converted to uracil (U), while methylated cytosines remain unchanged.
3. The DNA treated by the bisulfite in the step 2 is used as a template, 5 pairs of specific primer pairs in the table 5 are adopted to carry out PCR amplification by DNA polymerase according to a reaction system required by a conventional PCR reaction, and all primers adopt a conventional standard PCR reaction system and are amplified according to the following procedure.
The PCR reaction procedure was: 95 ℃,4 min- & gt (95 ℃,20 s- & gt 56 ℃,30 s- & gt 72 ℃ 2 min) 45 cycles- & gt 72 ℃,5 min- & gt 4 ℃ for 1h.
4. Taking the amplified product of the step 3, and carrying out DNA methylation analysis by a time-of-flight mass spectrum, wherein the specific method is as follows:
(1) Mu.l of Shrimp Alkaline Phosphate (SAP) solution (0.3 ml SAP [ 0.5U) was added to 5. Mu.l of PCR product]+1.7ml H 2 O) then incubated in a PCR apparatus (37 ℃,20 min. Fwdarw. 85 ℃,5 min. Fwdarw. 4 ℃,5 min) according to the following procedure;
(2) Taking out 2 mu.l of the SAP treated product obtained in the step (1), adding the product into a 5 mu l T-clear reaction system according to the instruction, and then incubating for 3 hours at 37 ℃;
(3) Taking the product of the step (2), adding 19 mu l of deionized water, and then carrying out deionized incubation on a rotary shaking table for 1h by using 6 mu g of Resin;
(4) Centrifuging at 2000rpm at room temperature for 5min, and loading 384SpectroCHIP with the micro supernatant by a Nanodispenser mechanical arm;
(5) Time-of-flight mass spectrometry; the data obtained were collected with the spectroacquisition v3.3.1.3 software and visualized by MassArray EpiTyper v 1.2.1.2 software.
Reagents used for the time-of-flight mass spectrometry detection are all kits (T-Cleavage MassCLEAVE Reagent Auto Kit, cat# 10129A); the detection instrument used for the time-of-flight mass spectrometry detection is Massary O R Analyzer Chip Prep Module 384, model: 41243; the data analysis software is self-contained software of the detection instrument.
5. And (5) analyzing the data obtained in the step (4).
Statistical analysis of the data was performed by SPSS Statistics 23.0.
Non-parametric tests were used for comparative analysis between the two groups.
The identification effect of a combination of multiple CpG sites on different sample groupings is achieved by logistic regression and statistical methods of the subject curves.
All statistical tests were double-sided, with p-values <0.05 considered statistically significant.
A total of 88 distinguishable peak patterns were obtained by mass spectrometry experiments. The methylation level at each CpG site of each sample can be automatically obtained by calculating the peak area according to the "methylation level=peak area of methylated fragments/(peak area of unmethylated fragments+peak area of methylated fragments)" formula using SpectroAcquin v3.3.1.3 software.
3. Analysis of results
1. Healthy controls, differences in methylation levels of FUT7 gene in blood of patients with coronary heart disease and cerebral apoplexy (2 years earlier than clinical onset time)
Blood of 342 coronary heart disease patients, 278 cerebral apoplexy patients and 612 healthy controls was used as a study material to analyze methylation levels of all CpG sites in genes (Table 6), wherein the coronary heart disease and cerebral apoplexy patients are asymptomatic when entering the group, and the patients are ill within 2 years after entering the group. The results show that the methylation level median of the healthy control gene is 0.20 (iqr=0.17-0.31), the methylation level median of the cerebral apoplexy gene is 0.17 (iqr=0.14-0.28), and the methylation level median of the coronary heart disease patient is 0.23 (iqr=0.19-0.32). As a result of comparative analysis of the methylation levels of the genes among the three, it was found that the methylation levels of all CpG sites in the genes of the patients suffering from cerebral apoplexy were significantly lower than those of the healthy controls (p <0.05, table 6), and the methylation levels of all CpG sites in the genes of the patients suffering from coronary heart disease were significantly higher than those of the healthy controls (p <0.05, table 6). Furthermore, the methylation level of all CpG sites in the gene was significantly higher in patients with coronary heart disease than in patients with stroke (p <0.05, table 6). Therefore, the methylation level of the FUT7 gene can be used for screening potential patients suffering from cerebral apoplexy and coronary heart disease in 2 years, and is a molecular marker with high clinical value.
TABLE 6 comparative healthy controls, methylation level differences between coronary heart disease and cerebral apoplexy patients (2 years earlier than clinical onset time)
2. Healthy controls, differences in methylation levels of FUT7 gene in blood of patients with coronary heart disease and cerebral apoplexy (1 year earlier than clinical onset time)
Blood of 137 patients with coronary heart disease, 110 patients with cerebral apoplexy and 612 healthy controls is used as a research material to analyze methylation level differences of all CpG sites in genes among the three (Table 7), wherein the patients with coronary heart disease and cerebral apoplexy have no symptoms when entering the group, and the patients with coronary heart disease and cerebral apoplexy are ill within 1 year after entering the group. The results show that the methylation level median of the healthy control gene is 0.20 (iqr=0.17-0.31), the methylation level median of the cerebral apoplexy gene is 0.15 (iqr=0.12-0.28), and the methylation level median of the coronary heart disease patient is 0.25 (iqr=0.23-0.36). By comparing the methylation levels of the three genes, the methylation level of all CpG sites in the gene of the cerebral apoplexy patient is found to be significantly lower than that of the healthy control (p <0.05, table 7), and the methylation level of all CpG sites in the gene of the coronary heart disease patient is found to be significantly higher than that of the healthy control (p <0.05, table 7). Furthermore, the methylation level of all CpG sites in the gene was significantly higher in patients with coronary heart disease than in patients with cerebral stroke (p <0.05, table 7). Therefore, the methylation level of the FUT7 gene can be used for screening potential patients suffering from cerebral apoplexy and coronary heart disease within 1 year in the population, and is a molecular marker with high clinical value.
Table 7, comparative healthy controls, methylation level differences between patients with coronary heart disease and cerebral apoplexy (1 year earlier than clinical onset time)
3. Methylation level differences between healthy controls and coronary heart disease and cerebral apoplexy of different clinical characteristics (within 2 years earlier than clinical onset time)
We compared and analyzed the methylation level difference of the genes of 342 coronary heart disease patients, 278 cerebral apoplexy patients and 612 healthy controls with different clinical characteristics, wherein the coronary heart disease patients and the cerebral apoplexy patients are asymptomatic when entering the group, and the patients are ill within 2 years after entering the group. As a result, it was found that the methylation level of all CpG sites of the gene in patients with coronary heart disease (occult or asymptomatic myocardial ischemia, angina pectoris, myocardial infarction, ischemic cardiomyopathy, sudden death) with different clinical characteristics was significantly different from that of healthy controls (p <0.05, table 8). Furthermore, we found that methylation levels of all CpG sites in FUT7 genes in stroke patients (hemorrhagic stroke, ischemic stroke) with different clinical characteristics were significantly different from healthy controls (p <0.05, table 8).
Table 8, compares methylation level differences between healthy controls and coronary heart disease and cerebral apoplexy of different clinical characteristics (2 years earlier than clinical onset time)
4. Methylation level differences between healthy controls and coronary heart disease and cerebral apoplexy of different clinical characteristics (within 1 year earlier than clinical onset time)
We compared and analyzed the methylation level difference of genes of 137 patients with coronary heart disease, 110 patients with cerebral apoplexy and 612 healthy controls with different clinical characteristics, wherein the coronary heart disease and the cerebral apoplexy are asymptomatic when entering the group, and the patients with coronary heart disease and cerebral apoplexy are ill within 1 year after entering the group. As a result, it was found that the methylation level of all CpG sites of the gene in patients with coronary heart disease (occult or asymptomatic myocardial ischemia, angina pectoris, myocardial infarction, ischemic cardiomyopathy, sudden death) with different clinical characteristics was significantly different from that of healthy controls (p <0.05, table 9). Furthermore, we found that methylation levels of all CpG sites in the gene of stroke patients (hemorrhagic stroke, ischemic stroke) with different clinical characteristics were significantly different from healthy controls (p <0.05, table 9). Thus, the methylation level of the FUT7 gene can be used to predict the likelihood of developing coronary heart disease and stroke disease of different clinical characteristics over a 1 year period.
Table 9, comparison of methylation level differences between healthy controls and coronary heart disease and cerebral apoplexy of different clinical characteristics (1 year earlier than clinical onset time)
5. Methylation level differences between patients with and without cardiac injury due to receipt of anti-tumor drugs within 2 years of the group
The methylation levels of all CpG sites in the FUT7 gene were analyzed using blood of 147 and 105 non-heart-injured patients as a study material (Table 10), wherein both the heart-injured and non-heart-injured patients were asymptomatic in the group, and were clinically diagnosed within 2 years after the group. The results showed that the methylation level was median of 0.27 (iqr=0.24-0.38), and that the methylation level was median of 0.22 (iqr=0.16-0.30) in patients without heart injury, and that the methylation level of FUT7 gene in blood of patients with heart injury due to treatment with antitumor drugs was found to be significantly higher than that in blood of patients without heart injury (p <0.05, table 10). Thus, the methylation level of the FUT7 gene can be used to predict the likelihood of heart damage occurring over a period of 2 years from receiving a tumor therapeutic.
TABLE 10 comparison of methylation level differences between heart injury and non-heart injury patients over the next 2 years
6. Methylation level differences between recurrence and non-recurrence of coronary heart disease, recurrence and non-recurrence of cerebral apoplexy within 2 years of prognosis
The methylation level of all CpG sites in the RPTOR gene was analyzed by taking blood of 118 patients with recurrent coronary heart disease and 165 non-recurrent coronary heart disease groups as a study material (Table 11), wherein the recurrent coronary heart disease patients and the non-recurrent coronary heart disease patients are asymptomatic when they are in the group, and are clinically diagnosed within 2 years after the group. The results showed that the methylation level of patients with recurrent coronary heart disease was median of 0.24 (iqr=0.22-0.34), the methylation level of non-recurrent coronary heart disease group was median of 0.21 (iqr=0.18-0.32), and the methylation level of RPTOR gene in the blood of patients with recurrent coronary heart disease was found to be significantly higher than that of non-recurrent coronary heart disease group (p <0.05, table 11). Thus, the methylation level of the FUT7 gene can be used to predict the likelihood of recurrence of coronary heart disease over a 2 year period.
The methylation level of all CpG sites in the RPTOR gene was analyzed using blood of 98 patients with recurrent cerebral apoplexy and 121 non-recurrent cerebral apoplexy as study materials (Table 11), wherein both recurrent cerebral apoplexy and non-recurrent cerebral apoplexy patients were asymptomatic when they were enrolled, and clinically diagnosed within 2 years after enrolling. The results showed that the methylation level of the patients with recurrent cerebral apoplexy was median of 0.16 (iqr=0.13-0.29), the methylation level of the non-recurrent cerebral apoplexy group was median of 0.18 (iqr=0.16-0.31), and the methylation level of the RPTOR gene in the blood of the patients with recurrent cerebral apoplexy was found to be significantly lower than that of the non-recurrent cerebral apoplexy group by comparing the methylation levels of the RPTOR gene with each other (p <0.05, table 11). Thus, the methylation level of the FUT7 gene can be used to predict the likelihood of recurrence of stroke disease over a 2 year period.
Table 11, comparison of methylation level differences between patients with recurrent and non-recurrent coronary heart disease and patients with recurrent and non-recurrent cerebral apoplexy within two years of prognosis
7. Methylation level differences between non-recurrence of cardiovascular and cerebrovascular disease and recurrence of different clinical characteristics (prognosis within 2 years)
We compared and analyzed the methylation level difference of FUT7 gene of 286 patients with non-recurrence of cardiovascular and cerebrovascular diseases and 216 patients with recurrence of cardiovascular and cerebrovascular diseases with different clinical characteristics. As a result, it was found that methylation levels of all CpG sites of the FUT7 gene in patients with coronary heart disease of different clinical characteristics (latent or asymptomatic myocardial ischemia, angina pectoris, myocardial infarction, ischemic cardiomyopathy) were significantly different from those of non-recurrent controls of coronary heart disease of different clinical characteristics (p <0.05, table 12). Furthermore, we found that methylation levels of all CpG sites in FUT7 genes in stroke patients with different clinical characteristics (hemorrhagic stroke, ischemic stroke) were significantly different from non-recurrent controls of stroke with different clinical characteristics (p <0.05, table 12). Thus, the methylation level of the FUT7 gene can be used to predict the likelihood of recurrence of coronary heart disease and stroke disease of different clinical characteristics over a 2 year period.
Table 12 compares the methylation level differences between non-recurrence of cardiovascular and cerebrovascular disease and recurrence of cardiovascular and cerebrovascular disease of different clinical characteristics (prognosis within 2 years)
8. Establishment of mathematical model for assisting cardiovascular and cerebrovascular disease diagnosis
The mathematical model established by the invention can be used for achieving the following purposes:
(1) Before clinical onset, early warning is carried out on individuals with coronary heart disease onset risks within 2 years in the crowd;
(2) Before clinical onset, individuals with coronary heart disease onset risks within 2 years in the crowd are pre-warned, and the method is suitable for various types of coronary heart diseases;
(3) Before clinical onset, individuals with cerebral apoplexy incidence risks within 2 years of the population are pre-warned.
(4) Before clinical onset, individuals with cerebral apoplexy incidence risks within 2 years of the population are pre-warned, and the method is suitable for cerebral apoplexy of various types;
(5) Before clinical onset, early warning is carried out on individuals with cerebral apoplexy and coronary heart disease onset risks within 2 years of the population, and coronary heart disease patients and cerebral apoplexy patients are distinguished;
(6) Before clinical onset, early warning is carried out on individuals with coronary heart disease onset risks within 1 year in the crowd;
(7) Before clinical onset, individuals with coronary heart disease onset risks within 1 year in the crowd are pre-warned, and the method is suitable for various types of coronary heart diseases;
(8) Before clinical onset, early warning is carried out on individuals with cerebral apoplexy onset risks within 1 year in the crowd;
(9) Before clinical onset, individuals with cerebral apoplexy incidence risks within 1 year in the crowd are pre-warned, and the method is suitable for cerebral apoplexy of various types;
(10) Before clinical onset, early warning is carried out on individuals with cerebral apoplexy and coronary heart disease onset risks within 1 year in the crowd, and coronary heart disease patients and cerebral apoplexy patients are distinguished;
(11) Before clinical onset, early warning is carried out on individuals in the crowd, which are at risk of heart injury due to treatment of tumor medicaments within 2 years;
(12) Early warning individuals with coronary heart disease recurrence risks within 2 years in prognosis population before clinical onset;
(13) Before clinical onset, early warning is carried out on individuals with recurrence risk of cerebral apoplexy within 2 years in prognosis population;
(14) Before clinical onset, individuals with recurrence risk of coronary heart disease within 2 years in prognosis crowd are pre-warned, and the method is suitable for various types of coronary heart disease;
(15) Before clinical onset, individuals with recurrence risk of cerebral apoplexy within 2 years in the prognosis population are pre-warned, and the method is applicable to cerebral apoplexy of various types.
The mathematical model is established as follows:
(A) Data sources: the methylation levels of 342 coronary heart disease patients, 278 cerebral stroke patients and 612 healthy control isolated blood samples of target CpG sites or 147 cardiac injury patients were combined together in 105 people without cardiac injury or 118 coronary heart disease recurrent patients and 165 non-recurrent patients or 98 cerebral stroke recurrent patients and 121 non-recurrent patients (combination of one or more of tables 1-3) (detection method is the same as in step two).
The data can be added with known parameters such as age, sex, white blood cell count and the like according to actual needs to improve the discrimination efficiency.
(B) Model building
Selecting any two different types of patient data, namely training sets, according to requirements (for example, coronary heart disease patients and healthy controls, cerebral apoplexy patients and healthy controls, coronary heart disease patients and cerebral apoplexy patients, latent or asymptomatic myocardial ischemia patients and healthy controls, angina patients and healthy controls, myocardial infarction patients and healthy controls, ischemic cardiomyopathy patients and healthy controls, sudden death patients and healthy controls, hemorrhagic cerebral apoplexy patients and healthy controls, ischemic cerebral apoplexy patients and healthy controls, cardiac injury patients and non-occurrence cardiac injury patients, and the collection of the above patient samples is earlier than the clinical onset time of the disease for 2 years; alternatively, coronary heart disease patients and healthy controls, cerebral apoplexy patients and healthy controls, coronary heart disease patients and cerebral apoplexy patients, latent or asymptomatic myocardial ischemia patients and healthy controls, angina patients and healthy controls, myocardial infarction patients and healthy controls, ischemic cardiomyopathy patients and healthy controls, sudden death patients and healthy controls, hemorrhagic cerebral apoplexy patients and healthy controls, ischemic cerebral apoplexy patients and healthy controls, and the above patient samples are collected earlier than the clinical onset time of the disease by 1 year, or coronary heart disease recurrence patients and non-recurrence patients, cerebral apoplexy recurrence patients and non-recurrence patients, and the above patient samples are collected within the 2 years later) are used as data for establishing a model, and statistical software such as SAS, R, SPSS and the like is used for establishing a mathematical model by a formula using a statistical method of two-class logistic regression. The numerical value corresponding to the maximum approximate dengue index calculated by the mathematical model formula is a threshold value or is directly set to be 0.5 as the threshold value, the detection index obtained by the sample to be tested after the sample is tested and substituted into the model calculation is more than the threshold value and is classified into one type (B type), less than the threshold value and is classified into the other type (A type), and the detection index is equal to the threshold value and is used as an uncertain gray area. When a new sample to be detected is predicted to judge which type belongs to, firstly, detecting methylation levels of one or more CpG sites on the FUT7 gene of the sample to be detected by a DNA methylation determination method, then substituting data of the methylation levels into the mathematical model (if known parameters such as age, sex, white cell count and the like are included in the model construction, the step simultaneously substitutes specific numerical values of corresponding parameters of the sample to be detected into a model formula), calculating to obtain a detection index corresponding to the sample to be detected, and then comparing the detection index corresponding to the sample to be detected with a threshold value, and determining which type of sample the sample to be detected belongs to according to a comparison result.
Examples: as shown in fig. 1, the methylation level of single CpG sites or the methylation level of a plurality of CpG sites in the training set is calculated by using a formula of two-class logistic regression through statistical software such as SAS, R, SPSS to establish a mathematical model for distinguishing the class a from the class B. The mathematical model is herein a two-class logistic regression model, specifically: log (y/(1-y))=b0+b1x1+b2x2+b3x3+ … +bnxn, where y is a detection index obtained after substituting a methylation value of one or more methylation sites of a sample to be tested into a model as a dependent variable, b0 is a constant, x1-xn is an independent variable which is a methylation value of one or more methylation sites of the sample to be tested (each value is a value between 0 and 1), and b1-bn is a weight given to each methylation site by the model. In specific application, a mathematical model is established according to methylation degrees (x 1-xn) of one or more DNA methylation sites of a sample detected in a training set and known classification conditions (class A or class B, respectively assigning 0 and 1 to y), so that a constant B0 of the mathematical model and weights B1-bn of each methylation site are determined, and a numerical value corresponding to a maximum approximate dengue index calculated by the mathematical model is used as a threshold value or a threshold value divided by 0.5 is directly set. And the detection index, namely the y value, obtained after the sample to be detected is tested and calculated by substituting the sample into the model is classified as B when the y value is larger than the threshold value, and classified as A when the y value is smaller than the threshold value, and the y value is equal to the threshold value and is used as an uncertain gray area. Where class a and class B are the corresponding two classifications (groupings of classifications, which is class a and which is class B, to be determined according to a specific mathematical model, no convention is made herein), such as: coronary heart disease patients and healthy controls, cerebral stroke patients and healthy controls, coronary heart disease patients and cerebral stroke patients, latent or asymptomatic myocardial ischemia patients and healthy controls, angina patients and healthy controls, myocardial infarction patients and healthy controls, ischemic cardiomyopathy patients and healthy controls, sudden death patients and healthy controls, hemorrhagic cerebral stroke patients and healthy controls, ischemic cerebral stroke patients and healthy controls, heart damage patients and non-heart damage patients, and the collection of the above patient samples is earlier than the clinical onset time of the disease for 2 years; alternatively, coronary heart disease patients and healthy controls, cerebral stroke patients and healthy controls, coronary heart disease patients and cerebral stroke patients, occult or asymptomatic myocardial ischemia patients and healthy controls, angina patients and healthy controls, myocardial infarction patients and healthy controls, ischemic cardiomyopathy patients and healthy controls, sudden death patients and healthy controls, hemorrhagic cerebral stroke patients and healthy controls, ischemic cerebral stroke patients and healthy controls, and the collection of the above patient samples is within 1 year earlier than the clinical onset time of the disease; alternatively, patients with recurrent coronary heart disease and non-recurrent patients, patients with recurrent cerebral apoplexy and non-recurrent patients, and the samples of the patients are collected within 2 years after prognosis. When predicting a sample of a subject to determine which category the sample belongs to, blood of the subject is collected first, and then DNA is extracted therefrom. After the extracted DNA is converted by bisulfite, the methylation level of single CpG sites or the methylation level of a plurality of CpG sites of the FUT7 gene of a subject is detected by using a DNA methylation determination method, and methylation data obtained by detection are substituted into the mathematical model. If the methylation level of one or more CpG sites of the FUT7 gene of the subject is substituted into the mathematical model and then the calculated value, namely the detection index, is larger than the threshold value, the subject judges the class (B class) with the detection index in the training set larger than the threshold value; if the methylation level data of one or more CpG sites of the FUT7 gene of the subject is substituted into the mathematical model and then the calculated value, namely the detection index, is smaller than the threshold value, the subject belongs to the class (class A) with the detection index in the training set smaller than the threshold value; if the methylation level data of one or more CpG sites of the FUT7 gene of the subject is substituted into the mathematical model, and the calculated value, i.e. the detection index, is equal to the threshold value, the subject cannot be judged to be A class or B class.
Examples: the schematic diagram of fig. 2 illustrates methylation of preferred CpG sites of fut7_d (fut7_d_2, fut7_d_3, fut7_d_4, fut7_d_5, fut7_d_6, fut7_d_7, fut7_d_8, fut7_d_9 and fut7_d_10) and mathematical modeling for early warning of whether coronary heart disease will occur within 2 years: the methylation level data of the 9 distinguishable CpG site combinations of the potential coronary heart disease patients (earlier than the clinical onset time less than or equal to 2 years) and the health control training set (342 coronary heart disease patients and 612 health controls are used for establishing a mathematical model for distinguishing the coronary heart disease patients and the health controls in the early warning 2 years by using a formula of two-class logistic regression through R software, wherein the methylation level data of the 9 distinguishable CpG site combinations of the potential coronary heart disease patients (earlier than the clinical onset time less than or equal to 2 years) and the health control training set (342 coronary heart disease patients and 612 health controls are used for assigning 1 to male and 0 to female) and the white blood cell count.
The mathematical model is here a two-class logistic regression model, whereby the constants b0 of the mathematical model and the weights b1-bn of the individual methylation sites are determined, in this case in particular:
log (y/(1-y)) = -0.504+2.569 x fut7_d_2+1.556 x fut7_d_3-6.395 x fut7_d_4-1.238 x fut7_d_5+6.379 x fut7_d_6-1.345 x fut7_d_7+6.922 x fut7_d_8-2.943 x fut7_d_9-2.701 x fut7_d_10-0.028 x age (integer) +0.169 x sex (male assignment 1, female assignment 0) -0.014 x white blood cell number (unit 10) 9 /L). Wherein y is a detection index obtained by substituting the methylation values of 9 distinguishable methylation sites of the sample to be detected into the model according to the dependent variable, such as age, sex and white blood cell count. Under the condition that 0.5 is set as a threshold value, the methylation level of the 9 distinguishable CpG sites, namely FUT7_D_2, FUT7_D_3, FUT7_D_4, FUT7_D_5, FUT7_D_6, FUT7_D_7, FUT7_D_8, FUT7_D_9 and FUT7_D_10 of the sample to be tested, is tested and then is substituted into a model together with information of age, sex and white cell count thereof to calculate, and the obtained detection index, namely y value is larger than 0.5For patients with potential coronary heart disease onset within 2 years, less than 0.5 is classified as a healthy control, and if the potential coronary heart disease onset within 2 years is equal to 0.5, whether the potential coronary heart disease onset within 2 years is a healthy control is not determined. The area under the curve (AUC) calculation for this model was 0.75 (table 19).
Blood was collected from two subjects (subject No. 1, subject No. 2), DNA was extracted from the blood, and DNA was converted by bisulfite, and methylation levels of the 9 distinguishable CpG sites, fut7_d_2, fut7_d_3, fut7_d_4, fut7_d_5, fut7_d_6, fut7_d_7, fut7_d_8, fut7_d_9, and fut7_d_10, were detected by DNA methylation assay. And substituting the methylation level data obtained by detection together with the information of the age, sex and white blood cell count of the subject into the mathematical model for early warning whether coronary heart disease can occur within 2 years. The value calculated by the mathematical model of the subject No. 1 is 0.84 to be more than 0.5, and the subject No. 1 is judged to be a potential patient of coronary heart disease (clinical onset within 2 years in the future); subject No. 2 was calculated to have a value of 0.33 less than 0.5 by the mathematical model, and subject No. 2 was judged to be a healthy control (the healthy control standard was still met for the next 2 years). The detection result is consistent with the actual situation.
Examples: the schematic diagram of fig. 3 illustrates methylation of preferred CpG sites fut7_d_2, fut7_d_3, fut7_d_4, fut7_d_5, fut7_d_6, fut7_d_7, fut7_d_8, fut7_d_9 and fut7_d_10 of fut7_d for early warning of stroke in 2 years as a result of mathematical modeling: the methylation level data of the 9 distinguishable preferred CpG site combinations which are detected in cerebral apoplexy patients (clinical onset time is less than or equal to 2 years) and healthy control training sets (278 cerebral apoplexy patients and 612 healthy controls in this case) are combined, and the mathematical model for distinguishing the cerebral apoplexy patients in early warning 2 years and the healthy controls is established by using a formula of two-class logistic regression through R software, wherein the age and the sex (male assignment is 1 and female assignment is 0) of the patients and the white blood cell count. The mathematical model is here a two-class logistic regression model, whereby the constant b0 of the mathematical model and the weights b1 to bn of the individual methylation sites are determined, in this example in particular: log (y/(1-y)) = -1.694+1.138 times fut7_d_2+3.708 times fut7_d_3+4.525 times fut7_d_4-0.789 times fut7_d_5-7.505 times fut7_d_6-1.67Fut7_d_7-2.836 fut7_d_8-3.825 fut7_d_9-1.301 fut7_d_10+0.013 age (integer) -0.159 sex (male assigned 1, female assigned 0) +0.096 white blood cell count (unit 10) 9 L), wherein y is the detection index obtained by substituting the methylation values of 9 distinguishable methylation sites of the sample to be tested and the age, sex and white blood cell count into the model. Under the condition that 0.5 is set as a threshold value, the methylation level of the FUT7_D_2, FUT7_D_3, FUT7_D_4, FUT7_D_5, FUT7_D_6, FUT7_D_7, FUT7_D_8, FUT7_D_9 and FUT7_D_10 of the sample to be tested can be tested and then is calculated together with information of age, sex and white cell count of the sample to be tested, the obtained detection index, namely y value, is greater than 0.5 and is classified as a potential cerebral apoplexy patient with the onset within 2 years, less than 0.5 is classified as a healthy control, and the methylation level of the FUT7_D_8, FUT7_D_9 and FUT7_D_10 is not determined as a potential cerebral apoplexy patient with the onset within 2 years or a healthy control. The area under the curve (AUC) calculation for this model was 0.73 (table 19).
Blood was collected from two subjects (subject No. 3, subject No. 4), DNA was extracted from the blood, and DNA was converted by bisulfite, and methylation levels of the 9 distinguishable CpG sites, fut7_d_2, fut7_d_3, fut7_d_4, fut7_d_5, fut7_d_6, fut7_d_7, fut7_d_8, fut7_d_9, and fut7_d_10, were detected by DNA methylation assay. And substituting the methylation level data obtained by detection together with the information of the age, sex and white blood cell count of the subject into the mathematical model for early warning whether cerebral apoplexy can occur within 2 years. The value calculated by the cerebral apoplexy mathematical model of the subject No. 3 is more than 0.82 and is more than 0.5, and the subject No. 3 is judged to be a cerebral apoplexy potential patient (clinical morbidity within the next 2 years); and if the value calculated by the cerebral apoplexy mathematical model of the subject No. 4 is less than 0.5, the subject No. 4 is judged to be healthy control (the future 2 years still accord with the healthy control standard). The detection result is consistent with the actual situation.
Examples: methylation of preferred CpG sites FUT7_D_2, FUT7_D_3, FUT7_D_4, FUT7_D_5, FUT7_D_6, FUT7_D_7, FUT7_D_8, FUT7_D_9 and FUT7_D_10, illustrating FUT7_D, and mathematical modeling are used to pre-warn whether heart may occur within 2 years after oncologic drug therapyDiscrimination of injury: the methylation level data of the 10 distinguishable preferred CpG site combinations detected in the heart injury patients (clinical onset time. Ltoreq.2 years) and the heart injury-free patients as training sets (147 heart injury patients and 105 heart injury-free patients in this case) and the age (integer), sex (male assignment 1, female assignment 0), white blood cell count (unit 10) 9 L) a mathematical model for distinguishing between patients suffering from heart damage and those not suffering from heart damage within 2 years after treatment with a oncology drug was established by R software using the formula of a two-class logistic regression. The mathematical model is here a two-class logistic regression model, whereby the constants b0 of the mathematical model and the weights b1-bn of the individual methylation sites are determined, in this case in particular: the model three is specifically as follows: log (y/(1-y))=2.756-0.948×fut7_d_2+1.325×fut7_d_3-0.195×fut7_d_4-0.990×fut7_d_5+4.481×fut7_d_6-3.009×fut7_d_7+0.113×fut7_d_8-1.491×fut7_d_9+1.595×fut7_d_10-0.064×age (integer) +0.193×sex (male assigned 1, female assigned 0) +0.107×white blood cell number (unit 10) 9 /L). Wherein y is the detection index obtained by substituting the methylation values of 9 distinguishable methylation sites of the sample to be detected into the model according to the dependent variables such as age, sex and white blood cell count. Under the condition that 0.5 is set as a threshold value, the methylation level of the preferred CpG sites FUT7_D_2, FUT7_D_3, FUT7_D_4, FUT7_D_5, FUT7_D_6, FUT7_D_7, FUT7_D_8, FUT7_D_9 and FUT7_D_10 of the FUT7_D of the sample to be tested is tested and then is substituted into the model together with information of age, sex and white cell count of the FUT7_D, the obtained detection index, namely y value, is greater than 0.5, and is classified as a patient suffering from heart injury in 2 years after being treated by tumor drugs, heart injury does not occur in 2 years after being treated by the tumor drugs, and if the y value is less than 0.5, whether heart injury occurs in 2 years after being treated by the tumor drugs is uncertain. The area under the curve (AUC) calculation for this model was 0.72 (table 23).
Blood was collected from two subjects (subject No. 5, subject No. 6) to extract DNA, and the DNA thus extracted was converted by bisulfite, followed by DNA methylation measurement to determine the superiority of fut7_d in the subjectsMethylation levels of the 9 distinguishable CpG sites, FUT7_D_2, FUT7_D_3, FUT7_D_4, FUT7_D_5, FUT7_D_6, FUT7_D_7, FUT7_D_8, FUT7_D_9 and FUT7_D_10, were examined. The methylation level data obtained from the test are then combined with the age (integer), sex (male assigned 1, female assigned 0) and white blood cell count (unit 10) 9 and/L) substituting the information into the mathematical model of the heart injury. The value calculated by the heart injury mathematical model of the subject No. 5 is 0.81 to be more than 0.5, and the subject No. 5 is judged to be a patient with heart injury within 2 years after being treated by the tumor drug (clinical onset within 2 years in the future); and if the calculated value of the number 6 subject through the cerebral apoplexy mathematical model is less than 0.36 and is less than 0.5, the number 6 subject is judged to be a patient with heart injury within 2 years after being treated by the tumor medicament (the prognosis accords with the non-recurrence standard within 2 years). The detection result is consistent with the actual situation.
Examples: methylation of preferred CpG sites FUT7_D_2, FUT7_D_3, FUT7_D_4, FUT7_D_5, FUT7_D_6, FUT7_D_7, FUT7_D_8, FUT7_D_9 and FUT7_D_10 of preferred CpG sites FUT7_D are illustrated for the discrimination of early warning prognosis of whether coronary heart disease will recur within 2 years by mathematical modeling: the methylation level data of the 9 distinguishable preferred CpG site combinations detected in the patients with recurrent coronary heart disease (recurrent time less than or equal to 2 years) and non-recurrent coronary heart disease as the training set (118 patients with recurrent coronary heart disease and 165 non-recurrent coronary heart disease) and the age (integer), sex (male assignment 1 and female assignment 0), white blood cell count (unit 10) 9 L) a mathematical model for distinguishing between patients with recurrent coronary heart disease and patients without recurrent coronary heart disease within 2 years of prognosis was established by R software using a formula of a two-class logistic regression. The mathematical model is here a two-class logistic regression model, whereby the constants b0 of the mathematical model and the weights b1-bn of the individual methylation sites are determined, in this case in particular: log (y/(1-y)) = -3.702+0.897 x fut7_d_2-0.519 x fut7_d_3+1.418 x fut7_d_4+0.876 x fut7_d_5-5.421 x fut7_d_6+1.982 x fut7_d_7+1.116 x fut7_d_8+1.714 x fut7_d_9-0.279 x fut7_d_10-0.095 x age (integer) +0.202 x sex (male assignment 1, female assignment 0) +0.058 x white blood cell number (unit 10) 9 /L)。Wherein y is the detection index obtained by substituting the methylation values of 9 distinguishable methylation sites of the sample to be detected into the model according to the dependent variables such as age, sex and white blood cell count. Under the condition that 0.5 is set as a threshold value, the methylation level of the 9 distinguishable CpG sites, namely FUT7_D_2, FUT7_D_3, FUT7_D_4, FUT7_D_5, FUT7_D_6, FUT7_D_7, FUT7_D_8, FUT7_D_9 and FUT7_D_10 of the sample to be tested is tested and then calculated together with information of age, sex and white blood cell count of the CpG sites, and the obtained detection index, namely y value, is more than 0.5 and is classified as a patient suffering from recurrent coronary heart disease within 2 years, less than 0.5 is classified as a patient suffering from recurrent coronary heart disease within 2 years, and the patient suffering from recurrent coronary heart disease within 2 years is not determined as a patient suffering from recurrent coronary heart disease within 2 years after the test. The area under the curve (AUC) calculation for this model was 0.72 (table 23).
Blood was collected from two subjects (subject No. 7, subject No. 8), DNA was extracted from the blood, and DNA was converted by bisulfite, and methylation levels of the 9 distinguishable CpG sites, fut7_d_2, fut7_d_3, fut7_d_4, fut7_d_5, fut7_d_6, fut7_d_7, fut7_d_8, fut7_d_9, and fut7_d_10, of the preferred CpG sites of fut7_d were detected by DNA methylation assay. The methylation level data obtained from the test are then combined with the age (integer), sex (male assigned 1, female assigned 0) and white blood cell count (unit 10) 9 and/L) substituting the information into a mathematical model for early warning and prognosis of whether the coronary heart disease can recur within 2 years. The value calculated by the mathematical model of the coronary heart disease recurrence risk assessment of the subject No. 7 is more than 0.5, and the subject No. 7 is judged to be a patient with coronary heart disease recurrence within 2 years of prognosis (coronary heart disease recurrence within two years of prognosis); and if the value calculated by the mathematical model of the coronary heart disease recurrence risk assessment of the subject No. 8 is less than 0.5, the subject No. 8 is judged to be a coronary heart disease non-recurrence patient within 2 years of prognosis (the non-recurrence standard is still met within 2 years of prognosis). The detection result is consistent with the actual situation.
Examples: methylation of preferred CpG sites FUT7_D_2, FUT7_D_3, FUT7_D_4, FUT7_D_5, FUT7_D_6, FUT7_D_7, FUT7_D_8, FUT7_D_9 and FUT7_D_10 of preferred CpG sites FUT7_D of FUT7_D The module is used for judging whether cerebral apoplexy recurs within 2 years of early warning and prognosis: the methylation level data of the 9 distinguishable preferred CpG site combinations which have been detected in the training set (98 patients with recurrent cerebral stroke and 121 patients with non-recurrent cerebral stroke are used as controls) and the age (integer), sex (male assignment 1, female assignment 0), white blood cell count (unit 10) 9 L) establishing a mathematical model for distinguishing between stroke relapsing patients and stroke non-relapsing patients by R software using a formula of a two-class logistic regression. The mathematical model is here a two-class logistic regression model, whereby the constants b0 of the mathematical model and the weights b1-bn of the individual methylation sites are determined, in this case in particular: log (y/(1-y)) = -4.473+2.056-fut7_d_2-1.926-fut7_d_3+2.704-fut7_d_4-0.503-fut7_d_5-1.493-fut7_d_6+0.893-fut7_d_7-0.158-fut7_d_8-2.649-fut7_d_9+1.603-fut7_d_10+0.074-age (integer) -0.449-sex (male assignment 1, female assignment 0) +0.030-white blood cell number (unit 10) 9 /L). Wherein y is the detection index obtained by substituting the methylation values of 10 distinguishable methylation sites of the sample to be detected into the model according to the dependent variables such as age, sex and white blood cell count. Under the condition that 0.5 is set as a threshold value, the methylation level of the 9 distinguishable CpG sites, namely FUT7_D_2, FUT7_D_3, FUT7_D_4, FUT7_D_5, FUT7_D_6, FUT7_D_7, FUT7_D_8, FUT7_D_9 and FUT7_D_10 of the sample to be tested is tested and then calculated together with information of age, sex and white cell count of the CpG sites, and the obtained detection index, namely y value, is more than 0.5 and is classified as a patient with recurrent cerebral apoplexy within 2 years after prognosis, less than 0.5 is classified as a patient with non-recurrent cerebral apoplexy within 2 years after prognosis, and the methylation level is equal to 0.5, and is not determined as a patient with recurrent cerebral apoplexy within 2 years after prognosis or a patient with non-recurrent cerebral apoplexy. The area under the curve (AUC) calculation for this model was 0.71 (table 23).
Blood is collected from two subjects (subject 9, subject 10) to extract DNA, the extracted DNA is converted by bisulfite, and the preferred CpG sites FUT7_D_2, FUT7_D_3, FUT7_D_4 and FUT of FUT7_D of the subjects are measured by DNA methylationMethylation levels of the 9 distinguishable CpG sites, 7_D_5, FUT7_D_6, FUT7_D_7, FUT7_D_8, FUT7_D_9 and FUT7_D_10 were examined. The methylation level data obtained from the test are then combined with the age (integer), sex (male assigned 1, female assigned 0) and white blood cell count (unit 10) 9 and/L) substituting the information into a mathematical model for early warning and prognosis of whether cerebral apoplexy will recur within 2 years. The value calculated by the mathematical model of the risk assessment of the recurrence of cerebral apoplexy of the first-class subject is more than 0.5, and the first-class subject is judged to be a patient with recurrence of cerebral apoplexy within 2 years of prognosis (clinical onset within 2 years of prognosis); and if the value calculated by the cerebral apoplexy mathematical model of the second subject is less than 0.38 and less than 0.5, the second subject is judged to be a cerebral apoplexy non-recurrence patient within 2 years of prognosis (the non-recurrence control standard is still met within 2 years of prognosis). The detection result is consistent with the actual situation.
(C) Model Effect evaluation
According to the method, a method for distinguishing coronary heart disease patients from healthy controls, cerebral apoplexy patients from healthy controls, coronary heart disease patients from cerebral apoplexy patients, latent or asymptomatic myocardial ischemia patients from healthy controls, angina patients from healthy controls, myocardial infarction patients from healthy controls, ischemic cardiomyopathy patients from healthy controls, sudden death patients from healthy controls, hemorrhagic cerebral apoplexy patients from healthy controls, ischemic cerebral apoplexy patients from healthy controls, cardiac injury patients from cardiac injury patients, is established, and the collection of the above patient samples is earlier than the clinical onset time of the disease for 2 years; for distinguishing coronary heart disease patients from healthy controls, cerebral stroke patients from healthy controls, coronary heart disease patients from cerebral stroke patients, latent or asymptomatic myocardial ischemia patients from healthy controls, angina patients from healthy controls, myocardial infarction patients from healthy controls, ischemic myocardial patients from healthy controls, sudden death patients from healthy controls, hemorrhagic cerebral stroke patients from healthy controls, ischemic cerebral stroke patients from healthy controls, and the collection of the above patient samples is earlier than the clinical onset time of the disease by 1 year; for distinguishing between patients with recurrent coronary heart disease and non-recurrent patients, patients with recurrent cerebral stroke and non-recurrent patients, and the samples of the above patients were collected within a period of 2 years after prognosis, and the effectiveness thereof was evaluated by a subject curve (ROC curve). The larger the area under the curve (AUC) from the ROC curve, the better the differentiation of the model, the more efficient the molecular marker. The evaluation results after construction of mathematical models using different CpG sites are shown in tables 13, 14, 15, 16, 17 and 18. Table 13, table 14, table 15, table 16, table 17 and table 18,1 CpG site represents the site of any one CpG site in the fut7_d amplified fragment, 2 CpG sites represent the combination of any 2 CpG sites in_d, 3 CpG sites represent the combination of any 3 CpG sites in fut7_d, … … and so on. The values in the table are the range of values for the combined evaluation of the different sites (i.e., the results for any combination of CpG sites are within this range).
The above results show that the discrimination ability of the genes for each group (coronary heart disease patient and healthy control, cerebral apoplexy patient and healthy control, coronary heart disease patient and healthy control, latent or asymptomatic myocardial ischemia patient and healthy control, angina patient and healthy control, myocardial infarction patient and healthy control, ischemic myocardial patient and healthy control, sudden death patient and healthy control, ischemic cerebral apoplexy patient and healthy control, cardiac injury patient and non-occurrence of cardiac injury patient, and the collection of the above patient samples is earlier than the clinical onset time of the disease for 2 years, or coronary heart disease patient and healthy control, cerebral apoplexy patient and healthy control, coronary heart disease patient and cerebral apoplexy patient, latent or asymptomatic myocardial ischemia patient and healthy control, angina patient and healthy control, myocardial infarction patient and healthy control, ischemic myocardial patient and healthy control, sudden death patient and healthy control, hemorrhagic cerebral apoplexy patient and healthy control, ischemic cerebral apoplexy patient and healthy control, and the collection of the above patient samples is earlier than the clinical onset time of the disease for 1 year, or the number of the recurrence of the coronary heart disease patient and the recurrence time of the disease is increased in advance of the disease and the non-occurrence of the disease for 2 years.
CpG sites of Table 13, FUT7_D and combinations thereof for distinguishing healthy controls and cerebral stroke, healthy controls and coronary heart disease, cerebral stroke and coronary heart disease (2 years earlier than clinical onset time)
Note that: the data in the table are area under the curve (AUC).
CpG sites of Table 14, FUT7_D and combinations thereof for distinguishing healthy controls and cerebral stroke, healthy controls and coronary heart disease, cerebral stroke and coronary heart disease (1 year earlier than clinical onset time)
Note that: the data in the table are area under the curve (AUC).
Table 15, cpG sites of FUT7_D and combinations thereof for distinguishing healthy controls and patients with coronary heart disease and cerebral apoplexy with different clinical characteristics (2 years earlier than clinical onset time)
Note that: the data in the table are area under the curve (AUC).
CpG sites of Table 16, FUT 7D and combinations thereof for distinguishing healthy controls from patients with coronary heart disease and cerebral apoplexy with different clinical characteristics (1 year earlier than the clinical onset time)
Note that: the data in the table are area under the curve (AUC).
CpG sites of Table 17, FUT7_D and combinations thereof for distinguishing heart injury patients from heart injury-free patients, recurrence of coronary heart disease and non-recurrence of coronary heart disease, recurrence of cerebral apoplexy and non-recurrence of cerebral apoplexy
Note that: the data in the table are area under the curve (AUC), where heart damage is within 2 years prior to clinical onset and recurrence of coronary heart disease and stroke is within 2 years of prognosis.
Table 18, cpG sites of FUT7_D and combinations thereof are used to distinguish between cardiovascular and cerebrovascular recurrence of different clinical features and non-recurrence control (within 2 years of prognosis)
In addition, among the CpG sites shown in tables 1 to 4, there are cases where combinations of a few preferred sites are better in discrimination ability than combinations of a plurality of non-preferred sites. For example, the 9 distinguishable CpG sites shown in Table 19, table 20, table 21, table 22, table 23 and Table 24, FUT7_D_2, FUT7_D_3, FUT7_D_4, FUT7_D_5, FUT7_D_6, FUT7_D_7, FUT7_D_8, FUT7_D_9 and FUT7_D_10 are preferred sites for any 9 combinations of_D.
In summary, the CpG sites on the gene and various combinations thereof, the CpG sites on the FUT7_A fragment and various combinations thereof, the CpG sites on the FUT7_B fragment and various combinations thereof, the CpG sites on the FUT7_C fragment and various combinations thereof, the CpG sites on the FUT7_D fragment and various combinations thereof FUT7_D_2, FUT7_D_3, FUT7_D_4, FUT7_D_5, FUT7_D_6, FUT7_D_7, FUT7_D_8, FUT7_D_9 and FUT7_D_10CpG sites and various combinations thereof, and methylation levels of CpG sites on a, _a, _b, _ C, D, and various combinations thereof were measured for each group of subjects (coronary heart disease patients and healthy controls, cerebral stroke patients and healthy controls, coronary heart disease patients and cerebral stroke patients, occult or asymptomatic myocardial ischemia patients and healthy controls, angina patients and healthy controls, myocardial infarction patients and healthy controls, ischemic cardiomyopathy patients and healthy controls, sudden death patients and healthy controls, hemorrhagic cerebral stroke patients and healthy controls, ischemic cerebral stroke patients and healthy controls, cardiac injury patients and non-occurrence of cardiac injury patients, and the collection of the above patient samples was earlier than the clinical onset time of the disease for 2 years; alternatively, coronary heart disease patients and healthy controls, cerebral apoplexy patients and healthy controls, coronary heart disease patients and cerebral apoplexy patients, latent or asymptomatic myocardial ischemia patients and healthy controls, angina pectoris patients and healthy controls, myocardial infarction patients and healthy controls, ischemic cardiomyopathy patients and healthy controls, sudden death patients and healthy controls, hemorrhagic cerebral apoplexy patients and healthy controls, ischemic cerebral apoplexy patients and healthy controls, and the collection of the above patient samples is within 1 year earlier than the clinical onset time of the disease, or, coronary heart disease recurrent patients and non-recurrent patients, cerebral apoplexy recurrent patients and non-recurrent patients, and the collection of the samples of the patients is within 2 years after prognosis).
Table 19, optimal CpG sites of FUT7_D and combinations thereof for distinguishing healthy controls and cerebral stroke, healthy controls and coronary heart disease, cerebral stroke and coronary heart disease (2 years earlier than clinical onset time)
Note that: the data in the table are area under the curve (AUC).
Table 20, FUT7_D optimal CpG sites and combinations thereof for distinguishing healthy controls and cerebral apoplexy, healthy controls and coronary heart disease, cerebral apoplexy and coronary heart disease (1 year earlier than clinical onset time)
Note that: the data in the table are area under the curve (AUC).
Table 21, FUT7_D optimal CpG sites and combinations for discriminating healthy controls and patients with coronary heart disease and cerebral apoplexy with different clinical characteristics (2 years earlier than clinical onset time)
Note that: the data in the table are area under the curve (AUC).
Table 22, FUT 7D optimal CpG sites and combinations for discriminating healthy controls and patients with coronary heart disease and cerebral apoplexy with different clinical characteristics (1 year earlier than the clinical onset time)
Note that: the data in the table are area under the curve (AUC).
Table 23, optimal CpG sites of FUT7_B and combinations for discriminating cardiac injury and absence of cardiac injury, recurrence and non-recurrence of coronary heart disease, recurrence and non-recurrence of cerebral apoplexy
Note that: the data in the table are area under the curve (AUC), where heart damage is within 2 years prior to clinical onset and recurrence of coronary heart disease and stroke is within 2 years of prognosis.
Table 24, FUT7_D optimal CpG sites and combinations for discriminating between patients with cardiovascular and cerebrovascular recurrence with different clinical characteristics and non-recurrence controls (within 2 years of prognosis)
The present invention is described in detail above. It will be apparent to those skilled in the art that the present invention can be practiced in a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation. While the invention has been described with respect to specific embodiments, it will be appreciated that the invention may be further modified. In general, this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains. The application of some of the basic features may be done in accordance with the scope of the claims that follow.
Claims (10)
1. A methylation biomarker, characterized in that: the nucleotide sequence of the methylation biomarker is all or part of fragments shown in the following (A1) - (A4) in the FUT7 gene:
(A1) A DNA fragment shown in SEQ ID No.1 or a DNA fragment having 80% or more identity thereto;
(A2) A DNA fragment shown in SEQ ID No.2 or a DNA fragment having 80% or more identity thereto;
(A3) A DNA fragment shown in SEQ ID No.3 or a DNA fragment having 80% or more identity thereto;
(A4) A DNA fragment shown in SEQ ID No.4 or a DNA fragment having 80% or more identity thereto;
the methylation marker comprises a CpG site located on the nucleotide sequence of the methylation marker as shown in any one of the following (B1) - (B7):
(B1) Any one or more CpG sites in 4 DNA fragments shown as SEQ ID No.1, SEQ ID No.2, SEQ ID No.3 and SEQ ID No.4 in the FUT7 gene;
(B2) All CpG sites on the DNA fragment shown in SEQ ID No.2 and all CpG sites on the DNA fragment shown in SEQ ID No.4 in the FUT7 gene;
(B3) All CpG sites on the DNA fragment shown in SEQ ID No.3 and all CpG sites on the DNA fragment shown in SEQ ID No.4 in the FUT7 gene;
(B4) All CpG sites on the DNA fragment shown in SEQ ID No.2 and all CpG sites on the DNA fragment shown in SEQ ID No.3 in the FUT7 gene;
(B5) All CpG sites on the DNA fragment shown in SEQ ID No.2, all CpG sites on the DNA fragment shown in SEQ ID No.3 and all CpG sites on the DNA fragment shown in SEQ ID No.4 in the FUT7 gene;
(B6) All CpG sites or any 17 or any 16 or any 15 or any 14 or any 13 or any 12 or any 11 or any 10 or any 9 or any 8 or any 7 or any 6 or any 5 or any 4 or any 3 or any 2 or any 1 CpG sites in the DNA fragment shown in SEQ ID No.4 in the FUT7 gene;
(B7) All or any 8 or any 7 or any 6 or any 5 or any 4 or any 3 or any 2 or any 1 of the following CpG sites shown in 9 on the DNA fragment shown in SEQ ID No.4 of the FUT7 gene:
item 1: the DNA fragment shown in SEQ ID No.4 shows CpG sites from 56 th to 57 th positions of the 5' end;
item 2: the DNA fragment shown in SEQ ID No.4 shows CpG sites from 128 th to 129 th positions of the 5' end;
item 3: the DNA fragment shown in SEQ ID No.4 shows CpG sites from 211-212 positions of the 5' end;
item 4: the DNA fragment shown in SEQ ID No.4 shows CpG sites from 227 th to 228 th positions of the 5' end;
item 5: the DNA fragment shown in SEQ ID No.4 shows CpG sites from 249-250 positions of the 5' end;
item 6: the DNA fragment shown in SEQ ID No.4 shows CpG sites from 267 th to 268 th of the 5' end;
item 7: the DNA fragment shown in SEQ ID No.4 shows CpG sites from 348 th to 349 th positions of the 5' end;
item 8: the DNA fragment shown in SEQ ID No.4 shows CpG sites from 380-381 th position of the 5' end;
item 9: the DNA fragment shown in SEQ ID No.4 shows CpG sites from 441 to 442 positions of the 5' end;
the methylation biomarker is used for at least one of the following purposes:
(1) Auxiliary diagnosis of cardiovascular and cerebrovascular diseases or early warning of cardiovascular and cerebrovascular diseases before clinical onset;
(2) Auxiliary diagnosis of coronary heart disease or early warning of coronary heart disease before clinical onset;
(3) Auxiliary diagnosis of cerebral apoplexy or early warning of cerebral apoplexy before clinical onset;
(4) Auxiliary distinguishing coronary heart disease and cerebral apoplexy or early warning and distinguishing coronary heart disease and cerebral apoplexy before clinical onset;
(5) Auxiliary diagnosis of coronary heart disease with different clinical characteristics or early warning of coronary heart disease with different clinical characteristics before clinical onset;
(6) Auxiliary diagnosis of cerebral apoplexy with different clinical characteristics or early warning of cerebral apoplexy with different clinical characteristics before clinical onset;
(7) Auxiliary diagnosis of cardiac injury or early warning of cardiac injury prior to clinical onset;
(8) The cardiovascular and cerebrovascular disease recurrence monitoring is assisted or the cardiovascular and cerebrovascular disease recurrence is early-warned before clinical onset;
(9) Auxiliary coronary heart disease recurrence monitoring or early warning of coronary heart disease recurrence before clinical onset;
(10) Auxiliary cerebral apoplexy recurrence monitoring or cerebral apoplexy recurrence pre-warning before clinical onset;
(11) Auxiliary monitoring of coronary heart disease recurrence with different clinical characteristics or early warning of coronary heart disease recurrence with different clinical characteristics before clinical onset;
(12) Auxiliary monitoring of cerebral apoplexy recurrence with different clinical characteristics or early warning of cerebral recurrence with different clinical characteristics before clinical onset.
2. Use of the methylation biomarker of claim 1 in the manufacture of a product; the application of the product is at least one of the following:
(1) Auxiliary diagnosis of cardiovascular and cerebrovascular diseases or early warning of cardiovascular and cerebrovascular diseases before clinical onset;
(2) Auxiliary diagnosis of coronary heart disease or early warning of coronary heart disease before clinical onset;
(3) Auxiliary diagnosis of cerebral apoplexy or early warning of cerebral apoplexy before clinical onset;
(4) Auxiliary distinguishing coronary heart disease and cerebral apoplexy or early warning and distinguishing coronary heart disease and cerebral apoplexy before clinical onset;
(5) Auxiliary diagnosis of coronary heart disease with different clinical characteristics or early warning of coronary heart disease with different clinical characteristics before clinical onset;
(6) Auxiliary diagnosis of cerebral apoplexy with different clinical characteristics or early warning of cerebral apoplexy with different clinical characteristics before clinical onset;
(7) Auxiliary diagnosis of cardiac injury or early warning of cardiac injury prior to clinical onset;
(8) The cardiovascular and cerebrovascular disease recurrence monitoring is assisted or the cardiovascular and cerebrovascular disease recurrence is early-warned before clinical onset;
(9) Auxiliary coronary heart disease recurrence monitoring or early warning of coronary heart disease recurrence before clinical onset;
(10) Auxiliary cerebral apoplexy recurrence monitoring or cerebral apoplexy recurrence pre-warning before clinical onset;
(11) Auxiliary monitoring of coronary heart disease recurrence with different clinical characteristics or early warning of coronary heart disease recurrence with different clinical characteristics before clinical onset;
(12) Auxiliary monitoring of cerebral apoplexy recurrence with different clinical characteristics or early warning of cerebral recurrence with different clinical characteristics before clinical onset.
3. Use of a substance for detecting the methylation level of the methylation biomarker of claim 1 in the manufacture of a product; the application of the product is at least one of the following:
(1) Auxiliary diagnosis of cardiovascular and cerebrovascular diseases or early warning of cardiovascular and cerebrovascular diseases before clinical onset;
(2) Auxiliary diagnosis of coronary heart disease or early warning of coronary heart disease before clinical onset;
(3) Auxiliary diagnosis of cerebral apoplexy or early warning of cerebral apoplexy before clinical onset;
(4) Auxiliary distinguishing coronary heart disease and cerebral apoplexy or early warning and distinguishing coronary heart disease and cerebral apoplexy before clinical onset;
(5) Auxiliary diagnosis of coronary heart disease with different clinical characteristics or early warning of coronary heart disease with different clinical characteristics before clinical onset;
(6) Auxiliary diagnosis of cerebral apoplexy with different clinical characteristics or early warning of cerebral apoplexy with different clinical characteristics before clinical onset;
(7) Auxiliary diagnosis of cardiac injury or early warning of cardiac injury prior to clinical onset;
(8) The cardiovascular and cerebrovascular disease recurrence monitoring is assisted or the cardiovascular and cerebrovascular disease recurrence is early-warned before clinical onset;
(9) Auxiliary coronary heart disease recurrence monitoring or early warning of coronary heart disease recurrence before clinical onset;
(10) Auxiliary cerebral apoplexy recurrence monitoring or cerebral apoplexy recurrence pre-warning before clinical onset;
(11) Auxiliary monitoring of coronary heart disease recurrence with different clinical characteristics or early warning of coronary heart disease recurrence with different clinical characteristics before clinical onset;
(12) Auxiliary monitoring of cerebral apoplexy recurrence with different clinical characteristics or early warning of cerebral recurrence with different clinical characteristics before clinical onset.
4. Use of a substance for detecting the methylation level of a methylation biomarker according to claim 1 and a medium storing a mathematical model and/or a method of using a mathematical model for the preparation of a product; the application of the product is at least one of the following:
(1) Auxiliary diagnosis of cardiovascular and cerebrovascular diseases or early warning of cardiovascular and cerebrovascular diseases before clinical onset;
(2) Auxiliary diagnosis of coronary heart disease or early warning of coronary heart disease before clinical onset;
(3) Auxiliary diagnosis of cerebral apoplexy or early warning of cerebral apoplexy before clinical onset;
(4) Auxiliary distinguishing coronary heart disease and cerebral apoplexy or early warning and distinguishing coronary heart disease and cerebral apoplexy before clinical onset;
(5) Auxiliary diagnosis of coronary heart disease with different clinical characteristics or early warning of coronary heart disease with different clinical characteristics before clinical onset;
(6) Auxiliary diagnosis of cerebral apoplexy with different clinical characteristics or early warning of cerebral apoplexy with different clinical characteristics before clinical onset;
(7) Auxiliary diagnosis of cardiac injury or early warning of cardiac injury prior to clinical onset;
(8) The cardiovascular and cerebrovascular disease recurrence monitoring is assisted or the cardiovascular and cerebrovascular disease recurrence is early-warned before clinical onset;
(9) Auxiliary coronary heart disease recurrence monitoring or early warning of coronary heart disease recurrence before clinical onset;
(10) Auxiliary cerebral apoplexy recurrence monitoring or cerebral apoplexy recurrence pre-warning before clinical onset;
(11) Auxiliary monitoring of coronary heart disease recurrence with different clinical characteristics or early warning of coronary heart disease recurrence with different clinical characteristics before clinical onset;
(12) Auxiliary monitoring of cerebral apoplexy recurrence with different clinical characteristics or early warning of cerebral recurrence with different clinical characteristics before clinical onset;
the mathematical model is obtained according to a method comprising the following steps:
(A1) Detecting the methylation level of the methylation biomarker of claim 1 of n1 type a samples and n2 type B samples, respectively;
(A2) Taking methylation level data of the methylation biomarkers of claim 1 of all samples obtained in the step (A1), and establishing a mathematical model by a two-classification logistic regression method according to classification modes of A type and B type;
the using method of the mathematical model comprises the following steps:
(B1) Detecting the methylation level of the methylation biomarker of claim 1 in a test sample;
(B2) Substituting methylation level data of the methylation biomarker of claim 1 of the sample to be tested obtained in the step (B1) into the mathematical model to obtain a detection index; then comparing the detection index with a threshold value, and determining whether the type of the sample to be detected is A type or B type according to a comparison result;
the type a sample and the type B sample are any one of the following:
(C1) Potential patients with coronary heart disease and healthy controls for onset within the next 2 years;
(C2) Potential patients with stroke and healthy controls that developed within the next 2 years;
(C3) Coronary heart disease potential patients with onset in the next 2 years and cerebral apoplexy potential patients with onset in the next 2 years;
(C4) Coronary heart disease potential patients and healthy controls with different clinical characteristics of onset within the next 2 years;
(C5) Stroke potential patients and healthy controls of different clinical characteristics of onset within the next 2 years;
(C6) Potential patients with coronary heart disease and healthy controls for onset within the next 1 year;
(C7) Potential patients with stroke and healthy controls that developed within the next 1 year;
(C8) Coronary heart disease potential patients with onset in the next 1 year and cerebral apoplexy potential patients with onset in the next 1 year;
(C9) Coronary heart disease potential patients and healthy controls with different clinical characteristics of onset within the next 1 year;
(C10) Stroke potential patients and healthy controls of different clinical characteristics of the onset within the next 1 year;
(C10) Stroke potential patients and healthy controls of different clinical characteristics of the onset within the next 1 year;
(C11) Patients with and without heart injury due to treatment with tumor drugs in the next 2 years;
(C12) Patients with recurrent cardiovascular and cerebrovascular diseases and non-recurrent patients within 2 years of prognosis;
(C13) Coronary heart disease recurrent patients and non-recurrent patients within 2 years of prognosis;
(C14) Stroke relapsing patients and non-relapsing patients within 2 years of prognosis;
(C15) Coronary heart disease recurrent patients and non-recurrent patients with different clinical characteristics within 2 years of prognosis;
(C16) Cerebral stroke relapsing patients and non-relapsing patients with different clinical characteristics within 2 years of prognosis.
5. A kit comprising a substance for detecting the methylation level of the methylation biomarker of claim 1; the application of the kit is at least one of the following:
(1) Auxiliary diagnosis of cardiovascular and cerebrovascular diseases or early warning of cardiovascular and cerebrovascular diseases before clinical onset;
(2) Auxiliary diagnosis of coronary heart disease or early warning of coronary heart disease before clinical onset;
(3) Auxiliary diagnosis of cerebral apoplexy or early warning of cerebral apoplexy before clinical onset;
(4) Auxiliary distinguishing coronary heart disease and cerebral apoplexy or early warning and distinguishing coronary heart disease and cerebral apoplexy before clinical onset;
(5) Auxiliary diagnosis of coronary heart disease with different clinical characteristics or early warning of coronary heart disease with different clinical characteristics before clinical onset;
(6) Auxiliary diagnosis of cerebral apoplexy with different clinical characteristics or early warning of cerebral apoplexy with different clinical characteristics before clinical onset;
(7) Auxiliary diagnosis of cardiac injury or early warning of cardiac injury prior to clinical onset;
(8) The cardiovascular and cerebrovascular disease recurrence monitoring is assisted or the cardiovascular and cerebrovascular disease recurrence is early-warned before clinical onset;
(9) Auxiliary coronary heart disease recurrence monitoring or early warning of coronary heart disease recurrence before clinical onset;
(10) Auxiliary cerebral apoplexy recurrence monitoring or cerebral apoplexy recurrence pre-warning before clinical onset;
(11) Auxiliary monitoring of coronary heart disease recurrence with different clinical characteristics or early warning of coronary heart disease recurrence with different clinical characteristics before clinical onset;
(12) Auxiliary monitoring of cerebral apoplexy recurrence with different clinical characteristics or early warning of cerebral recurrence with different clinical characteristics before clinical onset.
6. The kit of claim 5, wherein: the kit further comprises a medium storing a mathematical model and/or a method for using the mathematical model as described in claim 4.
7. A system, comprising:
(D1) Reagents and/or instrumentation for detecting the methylation level of the methylation biomarker of claim 1;
(D2) A device comprising a unit X and a unit Y;
the unit X is used for establishing a mathematical model and comprises a data acquisition module, a data analysis processing module and a model output module;
the data acquisition module is configured to acquire (D1) methylation level data of the methylation biomarker of claim 1 of n1 type a samples and n2 type B samples detected;
the data analysis processing module is configured to receive methylation level data of the methylation biomarker of the claim 1 from n1 type A samples and n2 type B samples sent by the data acquisition module, and establish a mathematical model through a two-classification logistic regression method according to classification modes of the type A and the type B to determine a threshold value of classification judgment;
the model output module is configured to receive the mathematical model sent by the data analysis processing module and output the mathematical model;
the unit Y is used for determining the type of the sample to be detected and comprises a data input module, a data operation module, a data comparison module and a conclusion output module;
The data input module is configured to input (D1) the methylation level data of the methylation biomarker of claim 1 detected by the subject;
the data operation module is configured to receive methylation level data of the methylation biomarker of claim 1 of the person to be tested, sent by the data input module, and substitute the methylation level data of the methylation biomarker of claim 1 of the person to be tested into the mathematical model to calculate a detection index;
the data comparison module is configured to receive the detection index sent from the data operation module and compare the detection index with the threshold value determined in the data analysis processing module in the unit X;
the conclusion output module is configured to receive the comparison result sent by the data comparison module and output a conclusion of whether the type of the sample to be tested is A type or B type according to the comparison result;
the type a sample and the type B sample are any one of the following:
(C1) Potential patients with coronary heart disease and healthy controls for onset within the next 2 years;
(C2) Potential patients with stroke and healthy controls that developed within the next 2 years;
(C3) Coronary heart disease potential patients with onset in the next 2 years and cerebral apoplexy potential patients with onset in the next 2 years;
(C4) Coronary heart disease potential patients and healthy controls with different clinical characteristics of onset within the next 2 years;
(C5) Stroke potential patients and healthy controls of different clinical characteristics of onset within the next 2 years;
(C6) Potential patients with coronary heart disease and healthy controls for onset within the next 1 year;
(C7) Potential patients with stroke and healthy controls that developed within the next 1 year;
(C8) Coronary heart disease potential patients with onset in the next 1 year and cerebral apoplexy potential patients with onset in the next 1 year;
(C9) Coronary heart disease potential patients and healthy controls with different clinical characteristics of onset within the next 1 year;
(C10) Stroke potential patients and healthy controls of different clinical characteristics of the onset within the next 1 year;
(C11) Patients with and without heart injury due to treatment with tumor drugs in the next 2 years;
(C12) Patients with recurrent cardiovascular and cerebrovascular diseases and non-recurrent patients within 2 years of prognosis;
(C13) Coronary heart disease recurrent patients and non-recurrent patients within 2 years of prognosis;
(C14) Stroke relapsing patients and non-relapsing patients within 2 years of prognosis;
(C15) Coronary heart disease recurrent patients and non-recurrent patients with different clinical characteristics within 2 years of prognosis;
(C16) Cerebral stroke relapsing patients and non-relapsing patients with different clinical characteristics within 2 years of prognosis.
8. The methylation biomarker or use or kit or system according to any of claims 1 to 7, wherein: the time of clinical onset is 2 years earlier than the time of clinical onset or 1 year earlier than the time of clinical onset.
9. The use or kit or system according to any one of claims 2-8, wherein: the substance for detecting the methylation level of the methylation biomarker of claim 1 comprising primer pair a and/or primer pair B and/or primer pair C and/or primer pair D;
the primer pair A is a primer pair consisting of a primer A1 and a primer A2; the primer A1 is SEQ ID No.5 or single-stranded DNA shown in 11 th-35 th nucleotides of SEQ ID No. 5; the primer A2 is SEQ ID No.6 or single-stranded DNA shown in 32 th-56 th nucleotides of SEQ ID No. 6;
the primer pair B is a primer pair consisting of a primer B1 and a primer B2; the primer B1 is SEQ ID No.7 or single-stranded DNA shown in 11 th-35 th nucleotides of SEQ ID No. 7; the primer B2 is single-stranded DNA shown in SEQ ID No.8 or 32-56 nucleotides of SEQ ID No. 8;
the primer pair C is a primer pair consisting of a primer C1 and a primer C2; the primer C1 is SEQ ID No.9 or single-stranded DNA shown in 11 th-35 th nucleotides of SEQ ID No. 9; the primer C2 is SEQ ID No.10 or single-stranded DNA shown in 32 th-56 th nucleotides of SEQ ID No. 10;
The primer pair D is a primer pair consisting of a primer D1 and a primer D2; the primer D1 is SEQ ID No.11 or single-stranded DNA shown in 11 th-35 th nucleotides of SEQ ID No. 11; the primer D2 is single-stranded DNA shown in SEQ ID No.12 or 32-56 nucleotides of SEQ ID No. 12.
10. The use or kit or system according to any one of claims 2-9, wherein: detecting the methylation level of the methylation biomarker of claim 1 is detecting the methylation level of the methylation biomarker of claim 1 in a blood sample.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310083186.0A CN116287195A (en) | 2023-02-08 | 2023-02-08 | Molecular marker for auxiliary diagnosis of cardiovascular and cerebrovascular diseases |
| CN202410135157.9A CN118028449A (en) | 2023-02-08 | 2024-01-31 | Data processing device and system for early warning of cardiovascular and cerebrovascular diseases and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310083186.0A CN116287195A (en) | 2023-02-08 | 2023-02-08 | Molecular marker for auxiliary diagnosis of cardiovascular and cerebrovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116287195A true CN116287195A (en) | 2023-06-23 |
Family
ID=86826525
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310083186.0A Pending CN116287195A (en) | 2023-02-08 | 2023-02-08 | Molecular marker for auxiliary diagnosis of cardiovascular and cerebrovascular diseases |
| CN202410135157.9A Pending CN118028449A (en) | 2023-02-08 | 2024-01-31 | Data processing device and system for early warning of cardiovascular and cerebrovascular diseases and application thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410135157.9A Pending CN118028449A (en) | 2023-02-08 | 2024-01-31 | Data processing device and system for early warning of cardiovascular and cerebrovascular diseases and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN116287195A (en) |
-
2023
- 2023-02-08 CN CN202310083186.0A patent/CN116287195A/en active Pending
-
2024
- 2024-01-31 CN CN202410135157.9A patent/CN118028449A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118028449A (en) | 2024-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105671181B (en) | Gene marker, primer, probe and kit for detecting lung cancer | |
| CN112553334A (en) | Colorectal cancer detection kit or device and detection method | |
| WO2017054325A1 (en) | Breast cancer combined diagnosis markers and detection kit | |
| O'Connell et al. | Stroke-associated pattern of gene expression previously identified by machine-learning is diagnostically robust in an independent patient population | |
| Adamski et al. | Expression profile based gene clusters for ischemic stroke detection | |
| WO2017202185A1 (en) | Peripheral blood gene marker for screening benign and malignant small pulmonary nodules and use thereof | |
| JP5522348B2 (en) | Prognostic method and kit for adult T-cell leukemia / lymphoma | |
| CN111996249A (en) | Cancer diagnosis and disease course monitoring method | |
| CN107937514B (en) | Application of primer in preparation of product for diagnosing pulmonary tuberculosis | |
| CN116287195A (en) | Molecular marker for auxiliary diagnosis of cardiovascular and cerebrovascular diseases | |
| EP2844776B1 (en) | Cancer blood test using bc200 rna isolated from peripheral blood for diagnosis and treatment of invasive breast cancer | |
| CN116287196A (en) | Cardiovascular and cerebrovascular disease identification marker and application thereof | |
| CN116814773A (en) | Molecular marker for early warning and prognosis of cardiovascular and cerebrovascular diseases | |
| US20230332234A1 (en) | Reagents, methods and kits for identifying pregnant human beings at risk for placental bed disorder(s) | |
| CN113539365B (en) | Methylation markers for early diagnosis of cardiovascular and cerebrovascular diseases | |
| CN113528636B (en) | Calbindin gene methylation as a potential marker for early diagnosis of cardiovascular and cerebrovascular diseases | |
| JP7392224B2 (en) | miRNA diagnostic biomarker for drug-induced interstitial pneumonia with diffuse alveolar injury | |
| Xu et al. | Non-invasive diagnosis of primary Sjögren's syndrome using ultrasonography and transcriptome biomarkers | |
| CN117568458A (en) | Methylation marker for assisting diagnosis of cardiovascular and cerebrovascular diseases | |
| WO2019095541A1 (en) | Composition and method for diagnosing and predicting breast cancer bone metastases | |
| Rainer et al. | Use of plasma DNA to predict mortality and need for intensive care in patients with abdominal pain | |
| CN117568457A (en) | Methylation markers for diagnosing coronary heart disease | |
| CN109182520B (en) | Cervical cancer and precancerous lesion detection kit and application thereof | |
| US11807908B2 (en) | Genetic markers used for identifying benign and malignant pulmonary micro-nodules and the application thereof | |
| CN113817812B (en) | Protease gene methylation as potential marker for early diagnosis of cerebral apoplexy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 200072, 3rd to 4th floors, Building 10, No. 351 Yuexiu Road, Hongkou District, Shanghai Applicant after: Tengchen Biotechnology (Shanghai) Co.,Ltd. Address before: 210032 2nd floor, building 02, life science and technology Island, 11 Yaogu Avenue, Jiangbei new district, Nanjing, Jiangsu Province Applicant before: Nanjing Tengchen Biological Technology Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20230623 |
|
| WD01 | Invention patent application deemed withdrawn after publication |